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SUMMARY  
 
Background. Childhood obesity represents a major health concern worldwide due to its 
well established detrimental effect on cardiovascular (CV) and its negative impact on 
premature morbidity and mortality.  
Aim. To study the effects of pediatric obesity on CV system and to find clinical markers 
related to CV dysfunction and metabolic impairment, in order to precociously identify 
children at higher risk of an “unhealthy” metabolic profile and early complications. To 
investigate the reversibility of CV damage through a healthy-lifestyle program.  
Methods. Complete anthropometrical, biochemical and CV assessment has been 
performed in large cohorts of obese children and adolescents before and after a 12-
months behavioral program based on an isocaloric Mediterranen balanced diet plus an 
exercise traing regimen. 
Results. We demonstrated that obesity is associated with an abnormal CV response 
during childhood and that these alterations are related to the presence of insulin 
resistance, metabolic syndrome and hyperuricemia. The second study reported a 
worsened metabolic profile in obese children with an estimated glomerular filtration rate 
(eGFR) >1 SD or with high serum uric acid levels. Finally, we showed that a healthy-
lifestyle program could reverse CV disfunction in children and this effect is related with 
weight loss and the improvement of metabolic risk and sistemic blood pressure.  
Conclusions. CV damage begins precociously, during pediatric age. Our studies provides 
proof that some clinical markers, like insulin resistance, eGFR and serum uric acid are 
helpful during risk stratification and should be implemented in clinical practice to identify 
children at higher risk of obesity-related complications. Behavioral interventions could be 
an effective strategy to prevent childhood obesity and to reverse its detrimental effects.  
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RIASSUNTO  
 
Introduzione. A livello globale, l’obesità pediatrica rappresenta uno dei maggiori problemi 
di salute pubblica a causa dei suoi ben noti effetti sul sistema cardiovascolare (CV) e del 
suo impatto negativo su morbilità e mortalità precoci. 
Scopo. Scopo di questo lavoro è stato valutare gli effetti dell’obesità pediatrica sul sistema 
CV e identificare marcatori clinici correlati al danno CV e all’alterazione metabolica, al fine 
di individuare precocemente i bambini a maggior rischio di un profilo metabolico 
sfavorevole e di sviluppare complicanze precoci. È stata inoltre indagata la reversibilità 
della disfunzione CV attraverso un programma di cambiamento dello stile di vita. 
Metodi. Una valutazione atropometrica, biochimica e CV completa è stata eseguita in 
ampie coorti di bambini e adolescenti obesi prima e dopo 12 mesi di un trattamento 
comportamentale basato su una dieta mediterranea isocalorica e su un programma di 
esercizio fisico. 
Risultati. Abbiamo dimostrato che l’obesità è associata ad un’anomala risposta CV, anche 
in età pediatrica e che tali alterazioni sono correlate alla presenza di insulino-resistenza, 
sindrome metabolica e iperuricemia. Il secondo studio riporta la presenza di un profilo 
metabolico peggiore nei bambini obesi con un tasso presunto di filtrazione glomerulare 
(eGFR) >1 DS e con elevati livelli sierici di acido urico. Infine, abbiamo dimostrato che il 
cambiamento dello stile di vita, attraverso un programma comportamentale, può migliorare 
la disfunzione CV in età pediatrica e che tale effetto è correlato con il calo ponderale e con 
il miglioramento del quadro metabolico e della pressione arteriosa sistemica. 
Conclusioni. Il danno CV inizia precocemente, durante l’età infantile. Questi studi 
forniscono un’evidenza che alcuni marcatori clinici come l’insulino-resistenza, l’eGFR e 
l’acido urico sierico, sono utili per stratificare il rischio e la loro valutazione dovrebbe 
essere implementata nella pratica clinica al fine di identificare più precocemente possibile 
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quei bambini ad alto rischio di sviluppare complicanze obesità-correlate. La terapia 
comportamentale e il cambiamento dello stile di vita potrebbero essere strategie efficaci 
per prevenire l’obesità pediatrica e trattare i suoi effetti avversi. 
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Chapter 1 
General introduction and rationale 
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During the past three decades, the prevalence of pediatric obesity has risen worldwide. 
The definitions of overweight and obesity in children differ between epidemiological 
studies, making comparisons of cross-sectional prevalence data difficult. Nevertheless, 
several studies have examined change in prevalence within populations over time, and the 
results of these analyses are astounding. In western countries, the combined prevalence 
of childhood overweight and obesity is 47.1% and rates have increased from 16.5% in 
1980 to 23.2% in 2013 [1]. In Europe, the prevalence of overweight and obesity between 
school age children is 12.8% and 7%, respectively [2] and the International Obesity Task 
Force (IOTF) estimates that by 2020 the prevalence of these conditions will be greater 
than 35.0% [3]. 
  
Figure 1. Global prevalence of obesity in children and adolescents [1].   
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Childhood obesity is a multisystem disease and causes a wide range of serious 
complications, increasing the risk of premature morbidity and mortality and raising public-
health concerns [4]. In addition, obese children are more prone to become obese adults, 
with an enhanced risk of obesity-related complications [5].  
 
Figure 2. Complications of pediatric obesity [4]. 
 
 
 
A cluster of cardiovascular disease risk factors as hypertension, dyslipidaemia, chronic 
inflammation, increased blood clotting tendency, endothelial dysfunction, and 
hyperinsulinaemia has been identified in children as young as 5 years of age [6]. Among 
adolescents and young adults, the presence of cardiovascular disease risk factors 
correlates with asymptomatic coronary atherosclerosis, and lesions were more advanced 
in obese subjects [7-9]. Furthermore, in an Israeli cohort including 2.3 million adolescents, 
the obese group showed a hazard ratio of 3.5 for death from total cardiovascular causes 
[10]. Moreover, recent studies reported that pediatric obesity is often associated with 
current cardiovascular abnormalities and there is evolving evidence that clinical indicators 
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of atherosclerosis such as carotid artery intima-media thickness (CIMT), arterial stiffness 
and endothelial dysfunction are impaired in children with obesity [11-16]. Furthermore, 
childhood obesity besides increasing traditional cardiometabolic risk factors, can seriously 
hamper kidney function and renal dysfunction may start early during childhood, long 
before a diagnosis of hypertension and type 2 diabetes can be made, and it might be 
related to pediatric obesity [17]. 
However, mechanisms by which these effects are mediated have not been fully 
understood, suggesting that this issue requires immediate attention to prevent progressive 
cardiovascular and kidney damage. Therefore, the identification of precocious biomarkers 
and the detection of a “high risk” profile associated with obesity during childhood would 
allow the early diagnosis of complications and the institution of preventive and therapeutic 
measures that might reduce morbidity and mortality at long term follow up. 
 
Aim of the thesis 
The purpose of this thesis is to analyze the development of obesity-related complications 
in obese children and adolescents, to detect precocious biomarkers that could help the 
clinician identifying “high risk” subjects and to assess the potential effect of a healthy-
lifestyle intervention reverting cardiovascular dysfunction during pediatric age. 
To this purpose, the studies reported in the following chapters were conducted. 
The study presented in Chapter 2 demonstrates that obesity and metabolic syndrome are 
associated with abnormal cardiovascular response during childhood. This study shows 
that hyperuricemia can be an early marker of cardiovascular dysfunction suggesting that 
the routine determination of circulating levels of serum uric acid should be implemented 
during risk stratification among pediatric age.  
In Chapter 3, the association of biomarkers of obesity-related renal disease and 
cardiometabolic risk factors is discussed. This study shows a worsened metabolic profile in 
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obese children with normal estimated glomerular filtration rate (eGFR) higher than 1 
standard deviation or with abnormally high serum uric acid levels suggesting that eGFR 
and serum uric acid may be helpful in clinical practice to identify an unhealthy metabolic 
profile in pediatric obesity.  
The Chapter 4 reports the results of a perspective behavioral intervention on 
cardiovascular response in obese children and adolescents. This study demonstrates that 
pediatric cardiovascular dysfunction could be partially reversed by a healthy-lifestyle 
program, the cornerstone of childhood obesity treatment, via weight loss and the 
improvement of metabolic risk and sistemic blood pressure.  
Studies presented in Chapters 2 and 3 have been published in international journals. 
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Chapter 2 
 
 
This study demonstrates that obesity and metabolic syndrome are associated with 
abnormal cardiovascular response during childhood. Furthermore, hyperuricemia can be 
an early marker of cardiovascular dysfunction suggesting that the routine determination of 
circulating levels of serum uric acid should be implemented during risk stratification among 
pediatric age.  
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ABSTRACT  
 
Introduction. Childhood obesity is associated with cardiovascular abnormalities but little is 
known on the potential correlation between early cardiovascular and metabolic alterations. 
Aim. Aims of this study were 1) to evaluate early cardiovascular abnormalities in a large 
population of obese children and adolescents compared with a normal weight counterpart, 
2) to investigate their potential association with insulin resistance (IR), serum uric acid 
(sUA) and metabolic syndrome (MetS). 
Methods. This was a single-center case-control study. Eighty obese (OB) subjects (6–16 
years) and 20 normal weight (NW) matched controlswere consecutively recruited. In the 
whole population we performed an anthropometric and a cardiovascular assessment. OB 
patients also underwent an OGTT and biochemical evaluations. 
Results. OB children showed greater left atrial (LA) and ventricular (LV) dimensions and 
mass and higher carotid artery intima-media thickness (CIMT), compared with NW 
controls. TheBMI z-score,waist circumference, IR and sUA were positively related with LA 
and LV dimensions and mass. OB subjects with MetS (46.3%) showed greater LA 
diameter (p = 0.001) and LV area (p = 0.01) and volume (p = 0.04) compared with OB 
children without MetS. LA diameter and LV dimensions and mass were significantly 
dependent on the number of criteria for MetS. Mets, sUA and IR were significant predictors 
of left heart dimensions and mass in obese children. 
Conclusions. Obesity and MetS are associated with abnormal cardiovascular response 
during childhood. Hyperuricemia can be an earlymarker of cardiovascular dysfunction and 
the routine determination of circulating levels of sUA should be implemented during risk 
stratification among pediatric age. 
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INTRODUCTION 
 
Childhood obesity causes a wide range of severe complications, increasing the risk of 
premature morbidity and mortality [1]. In addition, obese children are more prone to 
become obese adults, with higher risk of cardiovascular diseases (CVD) [2]. A cluster of 
CVD risk factors has been identified in children as young as 5 years of age [3] and, among 
adolescents, their presence correlates with asymptomatic coronary atherosclerosis [4]. 
Pediatric obesity has been related to an impaired cardiac structure and function as left 
atrial (LA) and left ventricular (LV) dimensions and mass significantly greater than lean 
controls [5–8] and impaired diastolic and systolic function [6,9]. 
Atherogenesis and arterial wall damage begin during childhood and, there is evolving 
evidence that clinical indicators of atherosclerosis such as carotid artery intima-media 
thickness (CIMT), arterial stiffness, and endothelial function are altered in obese children 
[10,11]. 
Hyperuricemia has been recognized as a risk factor for CVD in adults being predictive of 
insulin resistance (IR), metabolic syndrome (MetS) and all its components [12]. However, 
little is known on the potential association between early cardiovascular alterations and 
hyperuricemia and MetS in obese children. 
The detection of a high cardiovascular risk profile associated with pediatric obesity and the 
identification of possible early markers of cardiovascular damage during childhood would 
let an early diagnosis of cardiovascular complications allowing prompt preventive 
therapeutic measures that might reduce cardiovascular morbidity and mortality at long 
term follow up. 
Therefore, aims of this study were 1) to evaluate early cardiovascular abnormalities in 
obese children and adolescents compared with a normal weight counterpart, 2) to 
investigate their potential association with IR, serum uric acid (sUA) and MetS. 
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SUBJECTS AND METHODS 
 
Study design and population 
This was a single-center longitudinal case-control study conducted at Division of Pediatrics 
in Piedmont Region, Italy. We consecutively enrolled 80 Caucasian obese (OB) children 
and adolescents, aged 6–16 years, and 20 normal weight, age and sex matched controls 
(NW). OB patients were eligible if they were generally healthy, obese according to the 
International Obesity Task Force (IOTF) criteria [13], and not on a weight-loss diet. 
Exclusion criteria were specific causes of endocrine or genetic obesity, type 1 or type 2 
diabetes, previous heart, respiratory, liver and kidney diseases, current or past use of 
hormonal or interfering therapies (lipid-lowering, hypoglycemic, or antihypertensive 
treatments). Control subjects were eligible if they were normal weight [13], with no history 
of organic or psychiatric diseases. The protocol was conducted in accordance with the 
declaration of Helsinki and was approved by the Local Ethic Committee (CE 95/12). 
Informed written consent was obtained from all subjects' parents. 
 
Anthropometric and biochemical variables 
Height, weight, waist circumference (WC), hip circumference (HC), systolic (SBP) and 
diastolic (DBP) blood pressure were measured as previously described [14] and bodymass 
index (BMI) was calculated. Pubertal stages were evaluated according to Tanner criteria. 
In the OB group, after a 12-h overnight fast, blood samples were taken for measurement 
of: glucose (mg/dL), insulin (µUI/mL), total cholesterol (mg/dL), high density 
lipoproteincholesterol (HDL-c, mg/dL), triglycerides (mg/dL), sUA (mg/dL), using 
standardized methods in the Hospital's Laboratory [14]. Low density lipoprotein-cholesterol 
(LDL-c) was calculated by the Friedwald formula. sUA (mg/dL) was measured by Fossati 
method reaction using uricase with a Trinder-like endpoint. Obese subjects also underwent 
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an OGTT (1.75 g of glucose solution per kg, maximum 75 g) and samples were drawn for 
the determination of glucose and insulin every 30 min. Insulin-resistance was calculated 
using the formula of homeostasis model assessment (HOMA)-IR. Insulin sensitivity at 
fasting and during OGTT was calculated as the formula of the Quantitative Insulin-
Sensitivity Check Index (QUICKI) and Matsuda index (ISI) [28]. Glucose was expressed in 
mg/dL (1 mg/dL = 0.05551 mmol/L) and insulin in µUI/mL (1 µUI/mL = 7.175 pmol/L) in 
each formula [15]. Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) 
were defined according to American Diabetes Association [16] and MetS by using the 
modified National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP 
III) criteria of Cruz and Goran [17]. 
 
Echocardiographic assessment 
Transthoracic echocardiogram using a Vivid 7 Pro ultrasound scanner (General Electric 
Healthcare, USA) was performed by a sonographer and the images were reviewed by an 
expert pediatric cardiologist, blinded to patients' clinical data. Measurements of left 
ventricle (LV end-diastolic diameter, LVEDD; LV end-systolic diameter, LVESD; 
interventricular septum at end diastole, IVSD; LV posterior wall at end diastole, LVPWD), 
relative wall thickness (RWT), left atrium diameter (LAD), the maximum LA volume, and 
LV ejection fraction were obtained according to established standards [18]. LV mass 
(LVM) was derived from the Devereux formula and indexed to body surface area (left 
ventricular mass index [LVMI]) [27]. Using pulsed wave Doppler, mitral inflow velocities, 
peak early diastolic velocity (E), peak late diastolic velocity (A), E/A ratio, were measured. 
Pulsed wave tissue Doppler of the lateralmitral annulus was used for themeasurement of 
early peak diastolic mitral annular velocity (E'). The E/E' ratio was calculated. 
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Vascular assessment 
Vascular measurements were performed with a high-resolution ultrasonography (Esaote 
MyLab25™Gold, Esaote, Italy) using a 8 mHz linear transducer and a 5 mHz convex 
transducer for the abdominal aorta, by an expert sonographer and images were then 
reviewed offline by an expert vascular surgeon blinded to patients' clinical status. CIMT, 
abdominal aortic diameter at maximum systolic expansion (Ds) and minimum diastolic 
expansion (Dd), brachial artery diameters, brachial artery peak systolic velocity (PSV) and 
end diastolic velocity (EDV) were measured as previously described and aortic strain (S), 
pressure strain elasticmodulus (Ep), pressure strain normalized by diastolic pressure (Ep*) 
and brachial artery flow-mediated dilation (FMD) were calculated. While S is the mean 
strain of the aortic wall, Ep and Ep* are the mean stiffness [19]. The brachial artery 
maximum diameter recorded following reactive hyperemia was reported as a percentage 
change of resting diameter (FMD = peak diameter – baseline diameter/baseline diameter) 
[20]. 
 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD), absolute values or 
percentages. A sample of 15 individuals has been estimated to be sufficient to 
demonstrate a difference of 10% in LV diameter with a SD of 0.44 cm with 90% power and 
a significance level of 95% in the Student t-test between obese and controls according to 
published data [6]. A cohort of 75 obese subjects has been estimated to be sufficient to 
demonstrate differences among numbers of MetS criteria (0–5 criteria according to NCEP-
ATPIII classification) [17]. Distributions of continuous variables were examined for 
skewness and were logarithmically transformed as appropriate. ANCOVAwas used to 
determine the differences between obese and control subjects. Covariates were sex, age 
and pubertal stage. Correlation of cardiovascular parameters with continuous values of 
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BMI zscore, WC, HOMA-IR, ISI, and sUA were examined using Pearson correlation 
coefficients. Partial correlation was used to correct for covariates. The stepwise regression 
model with two-tailed probability values and 95% confidence intervals was used to 
measure the strength of the association between cardiovascular variables and BMI z-
score and each specific MetS criteria (abdominal obesity, hypertension, 
hypertrygliceridemia, low HDL-c, glucose intolerance: model 1) and other metabolic 
impairments (Model 2: model 1 + sUA; Model 3: model 2 + HOMA-IR). Statistical 
significance was assumed at p<0.05. The statistical analysis was performed with SPSS for 
Windows version 17.0 (SPSS Inc., Chicago, IL, USA). 
 
RESULTS 
 
Anthropometric and cardiovascular characteristics 
Table 1 shows the auxological and cardiovascular data of the 80 OB (age 11.2 ± 2.7 yrs., 
47.5% females, 36.3% prepubertal, BMI zscore 2.32 ± 0.51) and 20 age-, sex- and 
pubertal status-matched NW subjects (age 10.9 ± 2.5 yrs., 60.0% females, 45.0% 
prepubertal, BMI z-score−0.76±0.98). After adjusting for age, sex and puberty, OB children 
showed greater LV dimensions (LVEDD p<0.02, LVESD p<0.02, IVSD p<0.0001, LVPWD 
p<0.001), area (p<0.0001), volume (p<0.002) and LVM (p<0.0001), LAD (p<0.005) and 
lower E/A ratio (p<0.005) compared with NW subjects. No differences were found in the 
E/E' ratio, LV systolic function, LVMI and RWT. OB patients had larger abdominal aortic 
(p<0.03) and brachial artery (p<0.006) diameters compared with NW controls. CIMT was 
significantly higher in the OB group (p<0.0001) while no difference between the two 
groups was shown in aortic strain (S) and stiffness (Ep, Ep*) and in FMD of the brachial 
artery. 
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Table 1. Clinical and cardiovascular data of 80 obese (OB) and 20 normal weight (NW) subjects. 
 
Values are number (%) or means ± SD. 
	 20	
Legend: A, peak velocity of late diastolic transmitral wave; after, 2 min after the release of the pneumatic 
cuff; AoDd, abdominal aortic diastolic diameter; AoDs, abdominal aortic systolic diameter; BAD brachial 
artery diameter; BMI, body mass index; CIMT, carotid intima media thickness; DBP, diastolic blood pressure; 
E, peak velocity of early diastolic transmitral wave; E', peak early diastolic velocity on mitral annulus; EDV, 
brachial artery end-diastolic velocity; EF, LV ejection fraction; Ep, pressure strain elastic modulus; Ep*, 
pressure strain normalized for DBP; FMD, brachial artery flow-mediated dilation; FS, LV fractional 
shortening; HR, heart rate; immediately after, the release of the pneumatic cuff; IVSD, interventricular 
septum diastolic dimension; LA, left atrium; LAD, LA end-systolic diameter; LV, left ventricle; LVEDD, LV 
end-diastolic dimension, LVESD, LV end-systolic dimension; LVPW, LV posterior wall diastolic dimension; 
N°, number of subjects; ns, not significant; p, percentile; PSV, brachial artery peak systolic velocity; RWT, 
relative wall thickness; S, aortic strain; SBP, systolic blood pressure; SDS, standard deviation score; WC, 
waist circumference. 
 
Associations between cardiovascular measurements and metabolic parameters 
In the whole population, after adjusting for age, sex and pubertal status, both BMI z-score 
and WC were positively associated with LV dimensions (LVEDD, LVESD, IVSD, LVPWD), 
area and volume, LVM, LVM index, RWT, LAD, CIMT, abdominal aortic and brachial artery 
diameters and negatively relatedwith the E/A ratio. A negative relationship was found 
between BMI z-score and aortic stiffness. 
After adjusting for age, sex and puberty, insulin-resistance at fasting was positively 
correlated with LV dimensions (LVEDD, IVSD, LVPWD), area and volume, LVM and LVMI, 
RWT, LAD, LA area and volume, abdominal aortic diameter and negatively with the E/A 
ratio while insulin sensitivity during OGTT was negatively related with IVSD, LVPWD, 
LVM, RWT, LAD and abdominal aortic diameter. 
sUA was directly associated with LVEDD, LVESD, LVM, LV area and volume, brachial 
artery diameters and negatively with the E/A ratio, even after adjustment for confounding 
factors (Table S1). 
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Associations between cardiovascular measurements and SBP and DBP are shown in 
Table S2 in the supplementary appendix. As regards lipid profile, after adjustment for 
confounding factors, total cholesterol was positively correlated with LVPWD and RWT; 
HDL-c was negatively related with LAD; LDL-c was directly associated with CIMT and 
triglycerides were positively correlated with LAD. Total cholesterol, LDL-c and triglycerides 
were negatively related with the E/A ratio. 
 
Impact of MetS and sUA 
Out of OB children, 37 (46.3%) matched the NCEP ATPIII criteria for MetS. Patients with 
MetS had greater LAD (p=0.001) and LV area (p=0.01) and volume (p=0.04) compared 
with OB subjects without MetS. 
LAD and LV area, volume and LVM were significantly dependent on the number of criteria 
of MetS. Increasing the number of matched criteria for MetS, LAD, LV area, volume and 
LVM significantly increased (Fig. 1). This correlation persisted after adjustment for HOMA-
IR for LAD, LV area and volume while was lost for LVM. 
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Figure 1. MetS criteria-dependent left atrium diameter (LAD) (mm), left ventricle (LV) area (cm2), LV 
volume (mL) and LV mass (LVM) (g) in 80 obese children and adolescents. Log transformation was used for 
skewed variables (LVM).  
*p<0.001; ** p<0.0001; §p<0.04. Significance was maintained when the model included homoeostasis model 
assessment of insulin resistance (HOMA-IR) as covariates for LAD, LV area and volume while was lost for 
LVM. 
 
Stepwise multiple regression analysis showed that BMI z-score, HDL-c ≤10th percentile 
and triglycerides ≥90th percentile were independent predictors of LAD (model 1 and 2). In 
model 3, only BMI z-score and HDL-c in addition to HOMA-IR were confirmed as 
significant predictors of increased LAD. LV area was predicted by BP ≥90th percentile and 
IGT (model 1). In model 2, only sUA and BP were significant predictors. In model 3, 
HOMA-IR and BP were found as significant predictors. LV volume was predicted by IGT 
and HDL-c ≤10th percentile (model 1). In model 2 and 3, sUA and HOMA-IR were the only 
significant predictors. Finally, LVM was predicted by BMI z-score and triglycerides ≥90th 
percentile. In model 2 and 3, BMI z-score, sUA, HOMA-IR and triglycerides were the only 
significant predictors (Table 2). 
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Table 2. Stepwise multiple regression analysis of BMI z-score, metabolic syndrome (MetS) components, 
serum uric acid (sUA) and insulin resistance (HOMA-IR) (as independent variables) on left atrium diameter 
(LAD), left ventricular (LV) area and volume and Log LV mass (dependent variables). 
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Legend: BP, blood pressure; CI, confidence interval; HDL-c, HDL-cholesterol; IGT, impaired glucose 
tolerance; p, percentile. 
Model 1: independent variables were BMI z-score and MetS components, (waist circumference ≥90th 
percentile; BP ≥90th percentile; triglycerides ≥90th percentile; HDL-c ≤10th percentile; impaired fasting 
glucose; impaired glucose tolerance). 
Model 2: independent variables were those of Model 1 plus sUA. 
Model 3: independent variables were those of Model 2 plus HOMA-IR. 
 
DISCUSSION 
 
In this study, we found that pediatric obesity negatively affected cardiac remodelling and 
impaired vascular structure. Furthermore, IR and sUA and the presence of MetS might 
play an additional adverse role during heart remodelling among children and adolescents. 
 
Cardiovascular alterations in pediatric obesity 
Our study showed marked variations in the LA and LV dimensions in OB children 
compared to NW. These findings are in line with some previous studies reporting that LA 
and LV dimensions are significantly greater in OB children compared to NW [6,8,10,21]. 
Several investigations have also reported greater LVM in OB children [5,6,8,10,22], and 
this has been detected as early as 2 years of age [22]. Interestingly, we found no 
differences when normalizing LVM to body surface area between the two groups [9,21] 
possibly related to the overcorrection of measurements (normalized for parameters 
including weight) required for the obese group. Moreover, hypertrophy and dilatation of the 
LV might represent a physiological response to the enhanced preload and afterload 
dependent to the increased BMI. 
Regarding heart function, we found a significant reduction in the E/A ratio in the OB group 
(mainly related to the increased inflow velocities during atrial contraction/A-velocities) and 
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no significant changes in E'-velocities or in the E/E'-ratio with a preserved global LV 
systolic function. Despite the well-known association between diastolic dysfunction and 
subsequent impaired systolic functional changes in the adulthood, this correlation is still 
conflicting when applied in pediatric subjects. 
The majority of studies, showed no difference between obese and normal weight children 
in the peak early mitral inflow velocity (E) and in the early diastolic mitral velocity assessed 
with PWTDI (E') as parameters for diastolic function [7,9,21]. According with our data, the 
lack of significant changes in early filling characteristics suggests an increased 
dependency of atrial filling related to a decreased LV early relaxation [9,21].  
In line with this, we also found increased systolic and diastolic abdominal aortic and 
brachial artery diameters in the OB group, which might represent an early marker of 
vascular remodelling. 
In fact, the assessment of CIMT is a sensitive clinical marker of atherosclerosis, predictive 
of CV morbidity and mortality in the adulthood and high-risk population. Interestingly, we 
found greater CIMT in obese patients, even in younger children, not related to the pubertal 
status and mainly due to the exposure to cardiovascular risk factors. 
 
Potential mechanisms linking obesity to cardiovascular dysfunction 
The excess of adipose tissue, enhanced metabolic activity and the subsequent increased 
preload, predispose to LA and LV dilatation, LV remodelling and hypertrophy as a 
compensatory mechanism for systolic and diastolicwall stress [23]. Obesity is associated 
with changes in the vascular system related to the development of early atherosclerosis, 
arterial hypertension and increase afterload. In this study the BMI z-score, waist 
circumference and systemic blood pressure are positively correlated with increasing CIMT. 
Surprisingly, we found an inverse relationship between the BMI z-score and arterial 
stiffness that might reflect an early compensatory mechanism depicted by the arteries that 
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try to contrast the afterload via structural changes (increased diameter and thickness) 
before the rise in stiffness. 
According to previous data, in our obese population, the HOMA-IR correlates with 
increasing heart and aortic dimensions and decreasing diastolic function while no 
association was found between IR and CIMT and arterial stiffness [24]. IR can potentially 
induce to a decreased myocardial glucose uptake and increased fatty acid oxidation 
resulting in the accumulation of toxic intermediates of fatty acid metabolism that finally 
lead to myocardial dysfunction and arteries enlargement. Furthermore, compensatory 
hyperinsulinemia induces LV hypertrophy through binding of insulin to cardiac insulin-like 
growth factor 1 receptors [25]. 
In our OB group, MetS was associated with greater heart dimension and mass with 
straightforward linear raises when increasing the number of matched criteria for MetS. 
Subjects who met the MetS criteria, presented worst metabolic parameters (dyslipidemia, 
dysglycemia) with higher prevalence of hypertension and altered BMI with a significant 
impact on cardiac structural alterations. Our data highlight the influence ofMetS also in the 
pediatric subset, suggesting the usefulness of an early MetS investigation implemented 
with prompt cardiovascular imaging examination and aggressive therapeutic strategy in 
the obese children in order to prevent future cardiovascular dysfunction. 
Another interesting finding of the current study is the association between sUA and 
cardiovascular adverse remodelling. The association between sUA and levels of individual 
MetS components and their clustering has been previously reported [25–27]. The 
Bogalusa Heart Study showed that elevated sUA plays a crucial role in the pathogenesis 
of MetS with an influence that begins during adolescence, suggesting that sUA may aid in 
the early identification and treatment of high risk individuals for MetS [27]. Indeed, in a 
group of 299 overweight/obese children aged 8–18 years from the STYJOBS/EDECTA 
cohort, sUA was the best predictor of unhealthy obesity [28]. Furthermore, recent 
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investigations, has suggested that sUA level is an independent predictor of hypertension in 
adulthood [12]. In addition, Viazzi et al. showed that sUA was directly related to SBP and 
DBP independently of puberty, gender, BMI z-score, HOMA and renal function in a cohort 
of children and adolescents [29]. These data were confirmed by Feig et al. that showed a 
correlation between the reduction of sUA and normalization of blood pressure in 66% of 
hyperuricemic adolescents with hypertension, as compared to 3% in controls [30]. Finally, 
a reduction in sUA improved body weight and related CVD risk factors in young patients 
with hyperuricemia [31]. Moreover, sUA is an independent risk factor for heath failure and 
is associated with increased cardiovascular mortality in adults and children [12]. Out of our 
knowledge, this is the first study that demonstrates an association between sUA and LV 
volume and mass that is independent of BMI z-score, MetS and insulin resistance in a 
large cohort of obese pediatric patients. Studies conducted in adult populations suggest 
that hyperuricemia is associated with cardiac remodelling and LV hypertrophy and that 
sUA could be a marker of subclinical myocardial dysfunction [32], but this data were not 
fully confirmed during childhood. Reschke et al. showed, in a population of 49 
hypertensive children of which 21 overweight/obese and not evaluated for the presence of 
MetS, that 1 mg/dL increase in sUA over the baseline value was associated with an 
increase in LVM of 20.2 g. However, this association was no longer significant after 
adjustment for confounding factors [33]. Increased sUA levels may contribute to the 
echocardiographic abnormalities associated with obesity through effects on endothelial 
dysfunction and inflammation. Although uric acid seems to have antioxidant activity in the 
extracellular environment, once entered the cells, including vascular and heart muscle 
cells and adipocytes, might promote several detrimental effects. Injurious impacts of sUA 
include intracellular reactive oxygen species production, an inhibitory effect on nitric oxide 
formation, induction of platelet aggregation, and pro-inflammatory activity [12], also in 
children [34]. Furthermore, sUA activates the renin-angiotensin system causing 
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hypertension. The renin-angiotensin system, in turn, has been proposed to cause LV 
hypertrophy and cardiac fibrosis though mechanisms including BP increase, direct action 
of angiotensin II on cardiac myocytes, and effects of aldosterone [32]. As suggested by 
Borghi and Cicero, sUA requires more attention in the evaluation of the metabolic risk 
profile of obese children and adolescents [35] and, based on our findings, it could be an 
early marker of cardiovascular dysfunction in this population allowing a prompt and 
effective preventive measures. 
 
Study limitations 
Our study has several potential limitations. The major limit is the relatively small size of the 
population. Moreover, our study was not a randomized controlled trial. We perform a 
prospective data collection, which is certainly susceptible to selection bias. Finally a more 
extensive use of vascular imaging modalities including speckle tracking echocardiography 
and cardiac MRI would have certainly improved the results of the current study. 
 
CONCLUSION 
 
In conclusion, this study shows that obesity andMetS are associated with abnormal 
cardiovascular response during childhood. Moreover, hyperuricemia can be an early 
marker of cardiovascular dysfunction and the routine determination of circulating levels of 
sUA should be implemented during risk stratification among children and adolescents. 
Further larger studies and randomized trials are warranted to confirm our findings. 
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artial correlation for body m
ass index (B
M
I) z-score, w
aist circum
eference (W
C
, cm
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B
M
I z-score 
W
C
 (cm
) 
H
O
M
A
-IR
 
ISI 
sU
A
 (m
g/dL) 
 
r 
P value 
r 
P value 
r 
P value 
r 
P value 
r 
P value 
H
R
 (b/m
in) 
0.085 
ns 
0.114 
ns 
0.174 
ns 
-0.137 
ns 
-0.060 
ns 
E
F (%
) 
-0.115 
ns 
-0.105 
ns 
0.060 
ns 
0.016 
ns 
-0.045 
ns 
FS
 (%
) 
-0.104 
ns 
0.015 
ns 
0.058 
ns 
-0.102 
ns 
-0.070 
ns 
LV
E
D
D
 (m
m
) 
0.218 
0.05 
0.355 
0.001 
0.266 
0.02 
0.059 
ns 
0.264 
0.03 
LV
E
S
D
 (m
m
) 
0.247 
0.02 
0.322 
0.002 
0.065 
ns 
0.052 
ns 
0.270 
0.02 
IV
S
D
 (m
m
) 
0.390 
0.0001 
0.420 
0.0001 
0.364 
0.001 
-0.291 
0.02 
0.001 
ns 
LV
P
W
D
 (m
m
) 
0.441 
0.0001 
0.556 
0.0001 
0.386 
0.001 
-0.275 
0.02 
0.132 
ns 
LA
D
 (m
m
) 
0.431 
0.0001 
0.451 
0.0001 
0.385 
0.001 
-0.385 
0.001 
0.131 
ns 
LV
 area (cm
2) 
0.294 
0.01 
0.515 
0.0001 
0.366 
0.001 
-0.023 
ns 
0.269 
0.02 
LV
 volum
e (m
L) 
0.278 
0.01 
0.470 
0.0001 
0.379 
0.001 
0.047 
ns 
0.290 
0.02 
LA
 area (cm
2) 
0.175 
ns 
0.199 
ns 
0.290 
0.01 
-0.061 
ns 
-0.050 
ns 
LA
 volum
e (m
L) 
0.142 
ns 
0.167 
ns 
0.317 
0.007 
-0.026 
ns 
-0.005 
ns 
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LV
 m
ass (g) 
0.438 
0.0001 
0.546 
0.0001 
0.445 
0.0001 
-0.269 
0.03 
0.225 
0.05 
LV
 m
ass index (g/m
2) 
0.266 
0.02 
0.245 
0.02 
0.287 
0.01 
-0.028 
ns 
0.134 
ns 
R
W
T 
0.351 
0.002 
0.332 
0.002 
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0.02 
-0.286 
0.02 
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ns 
M
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/A
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-0.244 
0.03 
-0.214 
0.05 
-0.253 
0.04 
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ns 
-0.229 
0.05 
M
itral E
/E
’ ratio 
-0.198 
ns 
-0.050 
ns 
-0.148 
ns 
0.155 
ns 
-0.080 
ns 
C
IM
T (m
m
) 
0.281 
0.01 
0.376 
0.0001 
0.065 
ns 
0.056 
ns 
0.056 
ns 
A
oD
s (m
m
) 
0.267 
0.01 
0.356 
0.001 
0.084 
ns 
-0.268 
0.03 
0.118 
ns 
A
oD
d (m
m
) 
0.197 
ns 
0.244 
0.02 
0.259 
0.02 
-0.073 
ns 
0.025 
ns 
S
 
0.114 
ns 
0.147 
ns 
-0.123 
ns 
-0.029 
ns 
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ns 
E
p (m
m
H
g) 
-0.228 
0.04 
-0.037 
ns 
0.116 
ns 
-0.005 
ns 
-0.060 
ns 
E
p* 
-0.313 
0.005 
-0.092 
ns 
0.063 
ns 
0.045 
ns 
-0.072 
ns 
B
A
D
 basal (m
m
) 
0.302 
0.008 
0.392 
0.0001 
-0.058 
ns 
0.089 
ns 
0.321 
0.007 
B
A
D
 after (m
m
) 
0.293 
0.01 
0.386 
0.0001 
-0.145 
ns 
0.189 
ns 
0.347 
0.003 
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D
 (%
) 
-0.187 
ns 
-0.154 
ns 
-0.114 
ns 
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ns 
-0.192 
ns 
P
S
V
 basal (cm
/sec) 
-0.090 
ns 
-0.080 
ns 
0.165 
ns 
-0.127 
ns 
-0.012 
ns 
E
D
V
 basal (cm
/sec) 
0.034 
ns 
0.133 
ns 
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ns 
-0.130 
ns 
0.011 
ns 
P
S
V
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m
ediately after (cm
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-0.121 
ns 
-0.162 
ns 
0.271 
0.03 
-0.277 
0.05 
0.004 
ns 
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m
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-0.013 
ns 
-0.016 
ns 
0.198 
ns 
-0.082 
ns 
0.002 
ns 
P
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V
 after (cm
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0.021 
ns 
-0.076 
ns 
0.191 
ns 
-0.165 
ns 
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ns 
E
D
V
 after (cm
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0.028 
ns 
0.090 
ns 
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ns 
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ns 
0.042 
ns 
	V
alues in bold represent significant results. P
artial correlation w
as adjusted for gender, age and Tanner stage. Log transform
ation w
as used for skew
ed variables. 
For abbreviations see Table 1. 
Table S2. Partial correlation for systolic (SBP, mmHg) and diastolic (DBP, mmHg) blood pressure with 
cardiovascular measurements. 
 SBP DBP 
 r P value r P value 
HR (b/min) 0.174 ns 0.115 ns 
EF (%) 0.125 ns 0.085 ns 
FS (%) 0.202 0.05 0.187 ns 
LVEDD (mm) 0.501 0.0001 0.327 0.002 
LVESD (mm) 0.359 0.001 0.279 0.008 
IVSD (mm) 0.289 0.006 0.240 0.02 
LVPWD (mm) 0.257 0.02 0.249 0.02 
LAD (mm) 0.357 0.001 0.373 0.0001 
LV area (cm2) 0.402 0.0001 0.205 0.05 
LV volume (mL) 0.335 0.002 0.192 ns 
LA area (cm2) 0.219 0.04 0.187 ns 
LA volume (mL) 0.240 0.03 0.176 ns 
LV mass (g) 0.483 0.0001 0.409 0.0001 
LV mass index (g/m2) 0.354 0.0001 0.303 0.005 
RWT 0.185 ns 0.176 ns 
Mitral E/A ratio 0.163 ns 0.115 ns 
Mitral E/E’ ratio -0.009 ns -0.184 ns 
CIMT (mm) 0.240 0.02 0.263 0.01 
AoDs (mm) 0.176 ns 0.289 0.006 
AoDd (mm) 0.193 ns 0.283 0.007 
Aortic Strain, S 0.095 ns 0.114 ns 
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Ep (mmHg) 0.286 0.006 0.173 ns 
Ep* 0.220 0.04 0.184 ns 
BAD basal (mm) 0.135 ns 0.163 ns 
BAD after (mm) 0.114 ns 0.162 ns 
FMD (%) 0.167 ns 0.185 ns 
PSV basal (cm/sec) 0.142 ns 0.167 ns 
EDV basal (cm/sec) 0.076 ns 0.152 ns 
PSV immediately after (cm/sec) 0.087 ns 0.093 ns 
EDV immediately after (cm/sec) 0.136 ns 0.147 ns 
PSV after (cm/sec) 0.226 0.03 0.187 ns 
EDV after (cm/sec) 0.056 ns 0.115 ns 
	
Values in bold represent significant results. Partial correlation was adjusted for gender, age and Tanner 
stage. Log transformation was used for skewed variables. 
For abbreviations see Table 1. 
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Chapter 3 
 
 
This study shows a worsened metabolic profile in obese children with normal estimated 
glomerular filtration rate (eGFR) higher than 1 standard deviation or with abnormally high 
serum uric acid levels suggesting that eGFR and serum uric acid may be helpful in clinical 
practice to identify an unhealthy metabolic profile in pediatric obesity.  
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ABSTRACT  
 
Background. Childhood obesity represents a major health concern worldwide due to its 
well established detrimental effect on cardiovascular and its potential negative effect on 
kidney functions. However, biomarkers that can help diagnose early stages of kidney 
damage in obese children represent an unmet clinical need.  
Objectives. In this study, we asked whether the prevalence of microalbuminuria, 
estimated glomerular filtration rate (eGFR) or hyperuricemia recorded in a wide cohort of 
obese children and adolescents would positively correlate with cardiometabolic 
dysfunction in these subjects.  
Methods. We carried out a cross-sectional study on 360 obese children and adolescents 
between the ages of 3–18 years, enrolled in a tertiary care center. Clinical and 
biochemical evaluations including oral glucose tolerance tests (OGTTs) were performed 
on all patients. Microalbuminuria was defined as urinary albumin-to-creatinine ratio (u-
ACR) of 30–300 mg/g. All data are expressed as mean ± standard deviation (SD), 
absolute values or percentages. Sex age-specific and eGFR SDs were used for statistical 
analyses. Serum uric acid ≥5.5 mg/dL was considered abnormal.  
Results.  The prevalence of microalbuminuria was 6.4%. Except for a lower insulinogenic-
index, no correlations between microalbuminuria and cardiometabolic risk factors were 
detected. eGFR was <-1 SD and >1 SD in 1.4% and 60.8% of subjects, respectively. 
Subjects with an eGFR >1 SD had higher systolic blood pressure, liver enzymes, insulin 
resistance, glucose and insulin during OGTT, lower insulin sensitivity and a more prevalent 
microalbuminuria. Hyperuricemia (27.5%) increased the odds of hypertension, HDL ≤10th 
percentile and glucose ≥155.0 mg/dL after 60 minutes of OGTT.  
Conclusions. A worse cardiometabolic profile was observed in subjects with an eGFR >1 
SD compared to other subgroups. Therefore, pediatric obese patients with eGFR >1 SD or 
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hyperuricemia should be closely monitored for microalbuminuria and post-challenge 
glucose and insulin secretion, all potential indicators of renal dysfunction in these young 
patients.  
 
INTRODUCTION  
 
The rising prevalence of pediatric obesity is one of the most challenging public health 
issues worldwide. Most of the major concerns derive from the fact that childhood obesity, 
besides increasing traditional cardiometabolic risk factors, can seriously hamper kidney 
function [1]. In this regard, the recent global obesity epidemic has coincided with a 
dramatic rise in the prevalence of end-stage renal disease (ESRD) [1]. To make matters 
worse, emerging evidence suggests that renal dysfunction may start early during 
childhood, long before a diagnosis of hypertension with type 2 diabetes can be made, and 
it might be related to pediatric obesity [1].  
Since onset of the obesity-associated renal disease is generally subtle and asymptomatic, 
there is clearly an urgent need of biomarkers that could allow early detection of kidney 
dysfunction in obese children. In this regard, mounting evidence indicates that in adults the 
prevalence of microalbuminuria, which is often associated with nephropathy and 
atherosclerosis, positively correlates with the degree of obesity [2,3]. Furthermore, a 
relationship between microalbuminuria and obesity has also been reported in children and 
adolescents [1], although long-term studies in these patients have yet to be conducted. 
Interestingly, the association between estimated glomerular filtration rate (eGFR) and 
some cardiometabolic risk factors appears non-linear as either low- or high-normal eGFR 
has been associated with increased risk of metabolic diseases and mortality [2]. However, 
whether eGFR represents a bona fide cardiometabolic risk indicator, especially in pediatric 
patients, still remains to be determined [2,4].  
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In addition to microalbuminuria, hyperuricemia is another well-established risk factor 
for chronic kidney disease (CDK) in adults [5]. This is probably due to the detrimental 
effects exerted by uric acid once it permeates a cell, which obviously counteracts its 
antioxidant activity in the extracellular environment [6]. Therefore, hyperuricemia has a 
negative impact on both metabolism and longevity independent of traditional 
cardiometabolic risk factors [5]. However, data concerning hyperuricemia in obese children 
and adolescents are still lacking.  
Here, we have conducted a cross-sectional study on a wide cohort of obese pediatric 
patients to determine 1) the prevalence of microalbuminuria; 2) the distribution of age- and 
sex-specific eGFRs; 3) the prevalence of hyperuricemia; and 4) any correlations between 
microalbuminuria, eGFR and uric acid and other known cardiometabolic markers.  
 
MATERIALS AND METHODS  
 
Study design  
This was a cross-sectional study. Study quality was assessed. We consecutively recruited 
Caucasian children and adolescents, aged 3–18 years, referred to our Pediatric Endocrine 
Service from January 2011 to June 2014 for simple obesity. Subjects were eligible if 
generally healthy, overweight or obese, according to the IOTF criteria [7], and naïve to a 
weight-loss diet. Among children that had been previously subject to biochemical 
investigations due to any medical condition, only healthy children were included in the 
study. Subjects who refused to perform an oral glucose tolerance test (OGTT) were 
included only if they underwent fasting biochemical evaluations. Exclusion criteria were 
diagnosed or suspected endocrine or genetic obesity, type 1 diabetes and previous kidney 
diseases. Subjects referred to our Service for known comorbidities of obesity (e.g. glucose 
alterations, arterial hypertension, dyslipidemia, liver steatosis, hyperuricemia etc.) were 
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also excluded to avoid interferences due to previous lifestyle or pharmacological 
interventions.  
The protocol was conducted in accordance with the declaration of Helsinki and was 
approved by the Local Ethic Committee of AOU Maggiore della Carità of Novara (CE 
95/12). Informed consents was administered to all patients and parents of minors prior to 
the evaluations, and the study was carefully explained by the research team to all parents 
and children. Only those patients who provided a written informed consent were included 
in the study.  
 
Anthropometric and biochemical measurements  
Height was measured to the nearest 0.1 cm using a Harpenden stadiometer. Body weight 
was measured with light clothing to the nearest 0.1 kg using a mechanical column 
weighing scale (Wunder, weighing capacity 200 Kg). Body mass index (BMI) was 
calculated as body weight divided by squared height (kg/m2). The BMI standard deviation 
score (BMI-SDS) was calculated by the least median squares (LMS) method as previously 
described [8]. Waist circumference (WC) was measured at the high point of the iliac crest 
around the abdomen and was recorded to the nearest 0.1 cm. A non-elastic flexible tape 
was used, with the subjects being kept in a standing position with minimal respiration and 
no clothing covering the waist area or compressions on the skin. The waist-to-height ratio 
was calculated as well. Pubertal stages were determined by physical examination, using 
the criteria of Marshall and Tanner. Systolic BP (SBP) and diastolic BP (DBP) were 
measured three times at 2-minute intervals using a mercury sphygmomanometer with an 
appropriate cuff size after participants had been sitting quietly for at least 15 minutes, with 
their right arm being supported at the level of the heart, and feet resting flat on the floor, 
prior to other physical evaluations and at least 30 minutes after blood sampling. Mean 
values were used for all these analyses. Hypertension was determined only if BP values 
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recorded at enrollment and testing day were both found elevated. After a 12-hour 
overnight fast, blood samples were taken for measurement of: glucose (mg/dL), insulin 
(µUI/mL), total cholesterol (mg/dL), high density lipoprotein (HDL)-cholesterol (mg/dL), 
triglycerides (mg/dL), aspartate aminotransferase (AST, IU/L), alanine aminotransferase 
(ALT, IU/L), uric acid (mg/dL), creatinine (mg/dL), IGF1 (ng/mL), 25-hydroxy (OH) vitamin 
D (ng/mL), using standardized methods in the Hospital’s Laboratory [9]. Low-density 
lipoprotein (LDL)-cholesterol was calculated by the Friedwald formula. AST-to-ALT ratio 
was calculated. Uric acid (mg/dL) was measured by the Fossati method using uricase with 
a Trinder-like endpoint. Serum creatinine concentration (mg/dL) was measured by the 
enzymatic method. Glucose was determined by the hexokinase method (Slein Method, 
Advia 1200/1800/2400 Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany) with an 
intra-assay coefficient of variation of 0.7–2.3% (range 0.0 mg/dL-700.0 mg/dL). Insulin was 
determined by an immunoassay method (Advia Centaur1; Bayer Diagnostics, Leverkusen, 
Germany) with an intra- and inter-assay coefficient of variation of 3.2–4.6% and 2.6–5.9%, 
respectively (range 0.5 mU/L-300.0 mU/L). Urine albumin (mg/L) was determined by an 
advanced immunoturbidimetric assay, and urine creatinine (mg/dL) was measured using 
the enzymatic method.  
Subjects also underwent OGTT (1.75 g of glucose solution per kg, maximum 75 g), and 
samples were drawn for the determination of glucose and insulin every 30 minutes. The 
area under the curve (AUC) was calculated according to the trapezoidal rule. Insulin 
resistance was calculated using the formula for homeostasis model assessment (HOMA)-
IR. Insulin sensitivity at fasting and during OGTT was calculated with the formula of the 
Quantitative Insulin-Sensitivity Check Index (QUICKI) and Matsuda index (ISI). 
Insulinogenic (InsI) and disposition (DI) indexes were also calculated as previously 
reported [10]. The stimulus for insulin secretion in the increment in plasma glucose as the 
insulinogenic index was calculated as the ratio of the changes in insulin and glucose 
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concentration from 0 to 30 minutes (InsI). Βeta-cell compensatory capacity was evaluated 
by the disposition index defined as the product of the ISI and InsI (DI) [11]. Glucose was 
expressed in mg/dL (1 mg/dL = 0.05551 mmol/L) and insulin in µUI/mL (1 µUI/mL = 7.175 
pmol/L) in each formula. 
  
Definitions  
Subjects were classified as overweight or obese according to age- and sex-specific IOTF 
cut-offs [7]. WC percentiles were stratified according to sex and age, identifying abdominal 
obesity as the presence of WC ≥90th percentile or a waist-to-height ratio of 0.5 [10]. SBP 
and DBP values were evaluated according to percentiles for age, sex and height, and 
arterial hypertension was defined as SBP or DBP >95th percentile. Triglycerides, LDL- and 
HDL-cholesterol percentiles for age and sex were classified according to the Lipid 
Research Clinic Pediatric Prevalence Study. Dyslipidemia was defined as the presence of 
triglycerides ≥90th percentile, HDL- cholesterol ≤10th percentile or LDL ≥90th percentile. 
Impaired fasting glucose and impaired glucose tolerance were defined as fasting plasma 
glucose ≥100–125 mg/dL (5.6 to 6.9 mmol/ L) and 2-hour post-OGTT, glucose ≥140–199 
mg/dL (7.8 to 11.0 mmol/L), respectively. Uric acid ≥5.5 mg/dL was considered abnormal 
[12]. According to the NKF-K/DOQI Guidelines for chronic kidney disease (CKD) in 
children and adolescents [13], the eGFR was calculated using the modified Schwartz’s 
formula [14]: eGFR (mL/min/1.73 m2) = [0.413 x patient’s height (cm)] / serum creatinine 
(mg/dL). The normal renal function of patients [mean eGFR ± stan- dard deviation (SD) in 
mL/min/1.73 m2] was calculated based on age and gender according to NKF-K/DOQI 
Guidelines [13]. 2–12 year-old males and females: 133±27 mL/min/1.73 m2; 13– 21 year-
old males: 140±30 mL/min/1.73m2; and 13–21 year-old females: 126±22 mL/min/1.73 m2. 
Because only 6 subjects had eGFR lower or higher than ±2SD, the population was divided 
into four categories according to age and gender ±1SD (range: <-1 SD; -1-0 SD; 0–1 SD; 
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>1 SD). All subjects collected first-morning urine samples at rest. Urine albumin-to 
creatinine- ratio (u-ACR; mg/g) was calculated as follows: [urine albumin (mg/dL)/urine 
creatinine (g/dL)]. Microalbuminuria was defined as u-ACR ranging from 30 to 300 mg/g 
[15]. We collected two more samples from the subjects found positive for microalbuminuria 
to confirm the measurement. Microalbuminuria was diagnosed if all the three samples 
were found positive. 
  
Statistical analysis  
All data are expressed as mean ± SD, absolute values or percentages. In the case of 
microalbuminuria, the u-ACR mean values of the three first-morning samples were used 
as continuous variables. With an expected prevalence of 14% of microalbuminuria [6], a 
confidence level of 99.0% and a margin of error of 5.0%, a population size of 320 
individuals was estimated sufficient to reflect our target population. Skewed variables were 
logarithmically transformed. ANOVA was used to determine the differences among sex, 
the presence of microalbuminuria, hyperuricemia, and the eGFR subgroups with a 
Bonferroni post-hoc test for multiple comparisons in the latter. Analysis of covariance 
(ANCOVA) was also used for hyperuricemia and eGFR and covariates were age, sex, 
puberty and BMI (Model 1) or WC (Model 2), according to the significant relationship with 
dependent variables. Logistic regression was used to determine the association of 
microalbuminuria, eGFR and uric acid with the odds ratio (OR, 95% CI) of each 
cardiometabolic risk factor. Covariates of model 1 and 2 were also used in logistic 
regression for hyperuricemia and eGFR. Correlations as well as partial correlations were 
performed. Significance was assumed at p <0.05. The analysis was carried out with SPSS 
for Windows version 17.0 (SPSS Inc., Chicago, IL, USA). The database of the study is 
available upon request for validation or collaboration purposes as it includes other data 
(e.g. family history and other biochemical variables) not yet analyzed.  
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RESULTS  
 
Anthropometric and metabolic characteristics of patients  
Nineteen out of 379 subjects selected were excluded because they did not satisfy 
inclusion criteria (fifteen subjects did not have adequate blood sampling, and 4 were 
without at least 3 urine collections). The final dataset included 360 participants (180 males 
and 180 females), aged 3 to 18 years, with a mean age of 10.9±3.0 years. Of the 360 
participants, 18 subjects did not undergo OGTT (fifteen refused, 3 had analyses missing 
for technical problems), but had a complete fasting biochemical evaluation. Among 
patients 88% of them were obese, and 12% overweight. Almost all subjects had a WC  
≥90th percentile (97.8%) with an overall mean of the waist-to-height ratio of 0.63±0.11, 
without differences between sexes. The clinical and biochemical characteristics of subjects 
are reported in Table 1. Hypertension was diagnosed in 216 (60.0%) subjects. Eighty-eight 
subjects (24.4%) had triglycerides ≥90th percentile; 148 (41.1%) had HDL-cholesterol  
≤10th percentile; and 29 (8.0%) had LDL-cholesterol ≥90th percentile. Twenty subjects 
(5.5%) had impaired fasting glucose, 19 (5.2%) impaired glucose tolerance and 4 (1.1%) 
both metabolic dysfunctions. One patient had type 2 diabetes. 
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Table 1. Clinical and biochemical features of the study population according to sex. 
 
Data are expressed as mean±SD. p value <0.01*; < 0.0001†. OGTT data are available for 342 or 345 
subjects. 
Legend: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: 
body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration 
rate; F: female; GlcT0': fasting glucose; GlcT30',T60',T90',T120': post-challenge glucose; HDL-c: high 
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density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: 
insulinogenic index; InsT0': fasting insulin; IOTF: International Obesity Task Force; ISI: insulin sensitivity 
index; LDL-c: low density lipoprotein cholesterol; M: male; P: pubertal; PP: prepubertal; QUICKI: quantitative 
insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-creatinine ratio. 
 
Microalbuminuria and associations between eGFR, uric acid, and other 
cardiometabolic variables  
Microalbuminuria was detected in 6.4% (23/360) of subjects. In patients with or without 
microalbuminuria, uric acid was ≥5.5 mg/dL in 34.7% (8/23) and 27.0% (91/337) of them, 
respectively (p=0.278). All patients with microalbuminuria had eGFR >0 SD. In particular, 
69.6% (16/23) of them had eGFR >1 SD. In the entire cohort without microalbuminuria, 
91.7% (309/337) had eGFR >0 SD, and in 60.2% (203/337) of them the eGFR was >1SD.  
Subjects with microalbuminuria had lower insulin levels at 30-minute post-OGTT (81.8± 
72.8 mUI/L vs 122.3±163.5; p<0.02) and lower insulinogenic index (InsI) (0.74±5.08 vs 
2.24± 4.04; p<0.05) than those without it. No correlations between u-ACR as a continuous 
variable and cardiometabolic alterations were found.  
 
eGFR evaluation and its association with microalbuminuria, uric acid, and other 
cardiometabolic variables  
In 1.4% (5/360) of patients, eGFR was <-1 SD, while in 4 of them it was <-2 SD. 
Furthermore, eGFR was >1SD in 60.8% (219/360) of subjects, with 2 of them displaying 
an eGFR >2SD. Anthropometric and metabolic characteristics of subjects according to 
eGFR categories are reported in Table 2.  
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Table 2. Anthropometric and metabolic characteristics of the study population according to eGFR stratified 
for percentiles, age and sex dependent, based on NKF-K/DOQI Guidelines. 
 
Data are expressed as mean±SD. p value -1SD vs -1-0 SD: <0.05*; <0.01†. -1SD vs 0-1SD: <0.05‡. -1-0 SD 
vs 0±1 SD: <0. 05§; <0.0001¶; -1-0 SD vs >1SD: <0.05#; <0.01**. 0±1 SD vs >1SD: < 0.05††; < 0.01‡‡; < 
0.0001§§. ns: not significant. ANOVA analysis with a Bonferroni post-hoc test was used. OGTT data are 
available for 342 or 345 subjects. Legend: ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
AUC: area under the curve; BMI: body mass index; DI: disposition index; DBP: diastolic blood pressure; 
eGFR: estimated glomerular filtration rate; F: female; GlcT0': fasting glucose; GlcT30',T60',T90',T120': post-
challenge glucose; HDL-c: high density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of 
insulin resistance; InsI: insulinogenic index; InsT0': fasting insulin; IOTF: International Obesity Task Force; 
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ISI: insulin sensitivity index; LDL-c: low density lipoprotein cholesterol; M: male; P: pubertal; PP: prepubertal; 
QUICKI: quantitative insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-
to-creatinine ratio. 
 
Compared with subjects with eGFR <-1SD, patients with eGFR >1SD showed higher SBP, 
AST, ALT, glucose and insulin during OGTT, insulin resistance (Fig 1 , Panel A and B); 
they also had lower sensitivity indexes after both crude analysis and ANCOVA (Fig 1 , 
Panel C and D). 
 
Figure 1. Relationship between glucometabolic parameters and stratified estimated glomerular filtration 
rate (eGFR) levels. (Panel A) Plasma glucose levels (mg/dL) after 2-hour post-glucose tolerance test 
(OGTT) (T120'); (Panel B) homeostatic model assessment of insulin resistance (HOMA-IR); (Panel C) insulin 
sensitivity index (ISI); (Panel D) disposition index (DI); p value <0.05*; <0.01** after ANOVA corrected for 
confounding factors (i.e. sex, puberty, BMI). 
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Subjects with an eGFR within 0 and 1 SD had higher odds to have triglycerides <90th 
percentile in both crude and controlled models (model 2; OR 1.750; CI 1.002±3.056; p < 
0.04). 
eGFR was correlated with many variables in the crude model. After adjusting for age, sex, 
puberty, and BMI, eGFR was positively associated with WC, fasting insulin, glucose levels 
at 90 and 120 minutes, AUC and mean glucose, insulin at 120 minutes, mean insulin and 
u-ACR, and negatively associated with DPB, uric acid, ISI, and QUICKI. After adjusting for 
age, sex, puberty, and WC, eGFR was positively associated with fasting insulin, glucose 
levels at 90 and 120 minutes, AUC and mean glucose, HOMA-IR and u-ACR, and 
negatively associated with DPB, uric acid, ISI, and QUICKI (Table 3 ). 
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Table 3. Partial correlations between eGFR and microalbuminuria, uric acid and other cardiometabolic 
variables. 
 
ns: not significant. OGTT data are available for 342 or 345 subjects.  
Legend: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: 
body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration 
rate; GlcT0': fasting glucose; GlcT30',T60',T90',T120': post-challenge glucose; HDL-c: high density 
lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: insulinogenic 
index; InsT0': fasting insulin; ISI: insulin sensitivity index; LDL-c: low density lipoprotein cholesterol; QUICKI: 
quantitative insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-
tocreatinine ratio. 
Model 1: controlled for sex, age, puberty and BMI.  
Model 2: controlled for sex, age, puberty and waist circumference. 
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Hyperuricemia evaluation and its association with microalbuminuria, eGFR and 
other cardiometabolic variables 
Hyperuricemia was present in 27.5% (99/360) of subjects, of whom 8.1% (8/99) had 
microalbuminuria, whereas microalbuminuria was found in 5.7% (15/261) of subjects 
without hyperuricemia. 
Interestingly, 64.6% (64/99) of subjects with hyperuricemia had eGFR >1SD, and 26.3% 
(26/99) were between 0 and 1SD. In contrast, no subject with eGFR <-1 SD had 
hyperuricemia. 
Conversely, 59.4% (155/261) of subjects without hyperuricemia had eGFR >1 SD, and 
33.3% (87/261) were between 0 and 1 SD. 
Subjects with hyperuricemia were older, had higher BMI, BMI SDS, waist circumference, 
SBP, DBP, triglycerides, ALT and IGF-1 levels and lower HDL-cholesterol, AST, AST to 
ALT ratio, eGFR and u-ACR compared with those with normal acid uric levels. Moreover, 
subjects with hyperuricemia showed higher glucose and insulin, either at fasting or as 
responses to OGTT, associated with higher insulin resistance and lower insulin sensitivity 
than those without hyperuricemia. After controlling for confounding factors, subjects with 
hyperuricemia maintained higher levels of IGF-1 and lower eGFR compared to those with 
normal acid uric levels (Table 4).  
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Table 4. Anthropometric and metabolic characteristics of the study population according to uric acid. 
 
Data are expressed as mean±SD. ns: not significant. OGTT data are available for 342 or 345 subjects.  
Legend: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: 
body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration 
rate; F: female; GlcT0': fasting glucose; GlcT30',T60',T90',T120': post-challenge glucose; HDL-c: high 
density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: 
insulinogenic index; InsT0': fasting insulin; InsT30',T60',T90',T120': post-challenge glucose; ISI: insulin 
sensitivity index; LDL-c: low density lipoprotein cholesterol; M: male; QUICKI: quantitative insulin-sensitivity 
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check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-creatinine ratio; uric acid: high (≥5.5 
mg/dL); 25OH VitD: 25-0H vitamin D. 
Model 1: controlled for sex, age, puberty and BMI.  
Model 2: controlled for sex, age, puberty and waist circumference. 
 
Uric acid levels were positively associated with ALT, IGF-1, HOMA-IR, fasting insulin, 
glucose levels at 60, 90 and 120 minutes, AUC and mean glucose, insulin at 60 minutes, 
and negatively associated with HDL-cholesterol, AST to ALT ratio, eGFR, and QUICKI, 
also when corrected for covariates (Table 5 ). 
 
Table 5. Partial correlations between uric acid and microalbuminuria, eGFR and other cardiometabolic 
variables. 
 
ns: not significant.  
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Legend: ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BMI: 
body mass index; DI: disposition index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration 
rate; GlcT0': fasting glucose; GlcT30',T60',T90',T120': post-challenge glucose; HDL-c: high density 
lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; InsI: insulinogenic 
index; InsT0': fasting insulin; ISI: insulin sensitivity index; LDL-c: high density lipoprotein cholesterol; QUICKI: 
quantitative insulin-sensitivity check index; SBP: systolic blood pressure; u-ACR: urinary albumin-to-
creatinine ratio. 
Model 1: controlled for sex, age, puberty and BMI.  
Model 2: controlled for sex, age, puberty and waist circumference. 
 
Lastly, hyperuricemia was associated with hypertension (OR: 2.086, CI 1.257±3.460, p 
<0.003), HDL-cholesterol ≤10th percentile (OR: 2.001, CI 1.252±3.198; p <0.003) and 
glucose ≥155.0 mg/dL at 60 minutes after OGTT (OR: 2.350, CI 1.045±5.282; p <0.03) in 
both crude and controlled models. 
 
DISCUSSION 
 
This study shows a worsened metabolic profile in obese children with normal eGFR higher 
than 1SD or with abnormally high serum uric acid levels. In particular, post-OGTT glucose 
levels were found to be higher, albeit within standard cutoffs, in those individuals with 
eGFR >1 SD. Furthermore, subjects with microalbuminuria did not display a major 
impairment in their cardiometabolic alterations, although all of them had eGFR >0 SD. 
In recent years, a positive correlation between microalbuminuria and obesity in adult 
patients has been clearly established [3]. However, in pediatric patients such correlation 
appears to be less obvious and only partially understood probably due to the lack of 
consistent data on large-sized cohorts. In this regard, here we show a prevalence of 6.4% 
of microalbuminuria in a large cohort of obese children and adolescents, which is in good 
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agreement with previous data reporting prevalence of microalbuminuria ranging between 
0.3% and 10.1% in similar patient groups [16-21]. These studies, including ours, however 
appears to underestimate the prevalence of microalbuminuria when compared to other 
reports showing a much higher prevalence of microalbuminuria in obese children, which 
could go as high as 37.0% [22,23]. This discrepancy could be explained by different 
modalities of urine sample collection [22] or by the measurement of urinary albumin 
excretion rate per minute time rather than u-ACR [23]. Moreover, other variables such as 
postural changes and exercise before the testing session, as well as ethnicity, might 
account for data variability [24], even though no evidence indicating that this is indeed the 
case in obese children has been found in previous studies [18,19]. 
Associations between microalbuminuria and other cardiometabolic markers in obese 
children and adolescents have been reported in some [16,18,20-22,25] but not all studies 
[17,19,26], including ours. Although this lack of correlation could be explained by the 
young mean age of our patients or the low prevalence of microalbuminuria registered in 
these latter, our findings do not support a routine assessment of microalbuminuria in all 
obese children and adolescents. Interestingly, we find a lower insulinogenic index in 
subjects with microalbuminuria, which is in good agreement with a recent study 
demonstrating a positive correlation between microalbuminuria and HbA1c in obese 
Korean adolescents [21]. In this regard, it has been hypothesized that the prevalence of 
microalbuminuria progressively increased as plasma glucose values climbed through the 
`normal range' into the impaired range of glucose tolerance, suggesting that the effect of 
glucose may be continuous. Furthermore, frequent daily postprandial states of relatively 
higher glucose levels could increase oxidative stress on the vessels leading to increased 
urinary albumin excretion secondary to endothelial dysfunction [16]. 
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Moreover, because HbA1c and insulinogenic-index are both related to insulin-resistance, 
also the latter could be a responsible for this alteration. This is in agreement with the 
evidence that insulin-resistance contributes to micro and macrovascular disease [1,16]. 
Since our results appear to indicate that subjects with eGFR >0SD have microalbuminuria 
and a suboptimal metabolic phenotype, further longitudinal studies on larger populations 
are clearly needed to fully establish whether eGFR could be used as a useful marker to 
stratify high-risk obese youths. 
According to NKF-K/DOQI guidelines [13], we also report eGFR <-1SD in 1.4% of our 
population, who was free of known CKDs. Based on a normal population distribution, a 
much greater percentage would be expected to be below -1SD and again below normal -
2SD. The fact that the majority of our subjects were stratified above 0 and, to a greater 
extent, 1SD indicates a quite alarming skewed distribution of eGFR in obesity, in 
agreement with some [27], but not all authors [20,28]. In fact, differently by us, the 
distribution observed in the National Health and Nutrition Examination Survey (NHANES) 
resulted toward lower eGFR beyond what is expected. However, the NHANES cohort 
included only adolescents aged 12±19 years of general U.S. population [28], while our 
population was much younger. These contrasting findings could be due also to different 
obesity trajectories or different formulas used to determine eGFR from serum creatinine 
concentration (i.e Jaffè  technique vs  Schwartz's formula) [14]. Therefore, previous 
reports have clearly shown that adulthood obesity is associated with glomerular hyper-
perfusion and hyper-filtration as an early sign of physiologic maladaptation leading, in part, 
to afferent arteriolar vasodilatation [1]. Of note, we show that microalbuminuria was 
present only in subjects with eGFR >0SD in good agreement with a previous report [29]. 
Thus, our findings, together with the observation that childhood obesity positively 
correlates with a fast decline of eGFR over time, with a 2- to -3 fold higher risk of 
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developing ESRD [30], should prompt physicians to evaluate the possibility of renal 
dysfunction in obese children. 
We also show that subjects with eGFR >1SD presented with an increased burden of 
cardiometabolic alterations as recent studies in adults seem to suggest [2]. In particular, in 
our young patients with eGFR >1SD, systolic blood pressure, glucose, and insulin levels in 
response to OGTT and insulin resistance were higher, whereas insulin sensitivity was 
lower compared to other subgroups, suggesting a glucose dysregulation mainly after 
OGTT. The same condition was also present in patients with eGFR <-1SD, suggesting a 
U-shaped relationship, even though the low number of subjects in the left part of the curve 
does not allow us to draw any firm conclusions about its generalizability. A similar U-
shaped effect between eGFR, blood pressure and microalbuminuria has been recently 
reported by Di Bonito P. et al. [29], although these authors could not find a significant 
relationship between eGFR and the glyco-insulinemic profile at fasting. This discrepancy 
might be due to the different eGFR cutoff in adults used in this study. 
Overall, our findings raise the possibility that eGFR >1SD may be an early predictor of 
dysglycemia and pre-diabetes, a possibility that could be further explored by investigating 
the relationships among post-challenge glucose, insulin levels and kidney function in 
youths. Our data are also consistent with findings by Matsushita et al., who have recently 
shown that the inclusion of eGFR and u-ACR among traditional risk predictors greatly 
improved the discrimination of cardiometabolic outcomes in adults [4]. However, additional 
longitudinal studies are clearly needed to establish the evolution and distribution of eGFR 
in obese children and explain its pathophysiological significance over time. 
In our study, we show an inverse correlation between eGFR and uric acid, which is in line 
with previous reports on several adult populations [6] and adolescents with type 1 diabetes 
[31]. 
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While in the past hyperuricemia was thought to result from a decreased uric acid clearance 
due to kidney damage, it now seems that uric acid per se might play a role in the natural 
history of GFR decline [6]. In this regard, here we show that hyperuricemic patients are at 
increased risk of having a 1-hour post-OGTT glycemia ≥155.0 mg/dL. This cut-off seems 
to be associated with an increased metabolic risk in subjects with a post-challenge normal 
glucose tolerance as well as with the development of an overt type 2 diabetes rather than 
fasting glucose [32]. Moreover, serum uric acid levels are closely related to both early-
phase insulin secretion and 2-hour post-challenge glucose levels in adults with apparently 
normal glucose regulation [33]. 
To the best of our knowledge, this is the first study in a pediatric obese population where a 
positive association between uric acid and glucose response after OGTT has been found. 
In line with previous evidence [5], we confirm a worse cardiometabolic profile in subjects 
with hyperuricemia, which increased the odds of hypertension and HDL-cholesterol ≤10th  
percentile. 
In agreement with recent studies in adults [34], we also observed an association between 
uric acid and ALT, which suggests that uric acid may be an independent risk factor for liver 
diseases. 
Although serum uric acid seems a good predictor of renal and cardiometabolic diseases, 
its normal values in children and adolescents are still undefined. In this regard, we report 
an age-dependent effect on serum uric acid levels. Thus, the fixed cut-off is probably 
improper in the pediatric population, while a distribution according to age and sex may be 
more appropriate. 
All in all, our results are limited to a Caucasian population. We included only Caucasian 
children and adolescents because ethnic influences on microalbuminuria and serum uric 
acid have been reported [18,19,24,35]. Therefore, further studies on more heterogeneous 
populations are needed. 
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Our study has some limitations. First of all, the cross-sectional design does not allow us to 
conclude that there is a causal relationship between variables; longitudinal studies might 
clarify this aspect. Moreover, a normal-weight control group is lacking, because the study 
was performed in a tertiary referral center. Another limit is that microalbuminuria was 
measured on spot morning urine samples; however, spot u-ACR correlates very well with 
the urine collection at the 24-hour time point [19]. Furthermore, we failed to observe a 
normal distribution of eGFR in obesity, and a very low percentage of subjects could be 
stratified in the extreme tails (±2SD). Thus, studies on larger populations are needed to 
confirm our data and investigate the metabolic phenotype of those with an eGFR above or 
below ±2SD. 
On the other hand, our study includes a large sample of subjects as well as the availability 
of OGTT for the majority of patients. Moreover, microalbuminuria was confirmed on three 
samples, and eGFR was stratified according to the pediatric cut-off, unlike most 
publications on pediatric obesity. 
In conclusion, our study suggests that eGFR may be helpful in clinical practice to identify 
an unhealthy metabolic profile in pediatric obesity. Thus, more attention should be paid to 
this relatively inexpensive parameter. Therefore, in subjects with an eGFR >1SD or 
hyperuricemia, we encourage to investigate the early-phase insulin secretion and 2-hour 
post-challenge glucose levels. Serum uric acid seems to be another useful tool to 
diagnose subjects at high risk of metabolic impairment. However, studies based on larger 
population are needed to establish normal references values according to age and sex. 
Finally, based on our data, we strongly recommend the inclusion of microalbuminuria only 
in routine screenings of pediatric obese patients with eGFR greater than 1 SD. Further 
studies on large-sized pediatric cohorts are needed to confirm our finding also in obese 
children with an eGFR less than -2SD or greater than 2SD. 
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Chapter 4 
 
 
This chapter reports the results of a perspective behavioral intervention on cardiovascular 
response in obese children and adolescents. This study demonstrates that pediatric 
cardiovascular dysfunction could be partially reversed by a healthy-lifestyle program, the 
cornerstone of childhood obesity treatment, via weight loss and the improvement of 
metabolic risk and sistemic blood pressure.  
 
 
Effects of a healthy-lifestyle intervention on cardiovascular 
dysfunction in pediatric obesity 
 
 
 
 
 
 
 
 
 
 
Manuscript in preparation 
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ABSTRACT  
 
Introduction. Healthy-lifesyle interventions are the cornerstone treatment of childhood 
obesity. Pediatric obesity is associated with cardiovascular abnormalities but the 
reversibility of these alterations via behavioral programs are still debated. 
Aim of this study was to determine the effects of a 12 months healthy-lifestyle intervention 
based on diet plus physical activity on cardiovascular structure and function in obese 
children and adolescents.  
Methods. In this single-center perspective study we assessed changes in anthropometric, 
biochemical and a cardiovascular variables in 55 obese subjects (6–16 years) before and 
after a 12-months behavioral program based on an isocaloric Mediterranen balanced diet 
plus an exercise traing regimen (45-60 minutes daily sessions of aerobic training). 
Compliance was defined as a negative change in BMI z-score ≥10% from baseline. 
Results. At 12 months (T12), we observed a significant improvement of metabolic 
parameters (blood glucose during the OGTT, insulin resistance, HDL-cholesterol, and 
insulin sentivity) in compliant subjects (C). Treatment was effective in C subjects in 
increasing the mitral peak early diastolic velocity E (p<0.04) and the E/A ratio (p<0.02). 
Furtermore, in patients with a reduction in the number of NCEP-ATPIII metabolic 
syndrome criteria, behavioral intervention reduces LV area (p<0.01) and volume (p<0.05). 
Finally, intervention reduces carotid intima-media thickness (p<0.05) in subjects showing a 
decrease of the sistemic blood pressure.  
Conclusions. In obese children, cardiovascular impairement could be reversed by a 
healthy-lifestile intervention. To adopt prompt behavioral programs in childhood obesity is 
crutial both for prevention and for treatment of precocius complications and could have an 
exponential impact on long-term morbidity and mortality and global public health.  
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INTRODUCTION 
 
The rising prevalence of childhood obesity worldwide is one of the most important public 
health issues. Pediatric obesity is associated with a broad range of severe complications, 
increasing the risk of premature morbidity and mortality [1]. As a consequence of this 
pediatric obesity epidemic, an increase in the incidence of coronary heart disease and in 
the number of cardiovascular deaths is expected to occur in young adulthood. By 2035, it 
is estimated that the prevalence of coronary heart disease will increase from 5 to 16%, 
with more than 100.000 excess cases attributable to the increased obesity [2]. In obese 
adolescents, the hazard ratio for death in early adulthood from coronary heart disease is 
4.9, 2.6 from stroke, 2.1 for sudden death, and 3.5 for death from total cardiovascular 
causes [3]. Furthermore, we and others demonstrated that even during childhood, obesity 
impaired cardiac and vascular structure and function [4-10] and that some metabolic 
factors such as insulin resistance, serum uric acid and the presence of metabolic 
syndrome (MetS) might play an adverse role during heart remodelling among children and 
adolescents [4]. Seen this alarming data, a promt and aggressive therapeutic strategy in 
obese children is mandatory in order to reverse modifiable obesity-related risk factors, to 
prevent cardiovascular dysfunction and ultimately to reduce cardiovascular deaths. The 
treatment of pediatric obesity is usually based on exercise, dietary, and behavioral 
interventions. However, little is known about the reversibility of cardiac abnormalities in 
obese children and adolescents undergoing a lifestyle intervention program. 
Therefore, the primary purpose of this study was to determine the effects of a 12 months 
healthy-lifestyle intervention based on diet plus physical activity on cardiovascular 
structure and function in obese children and adolescents.  
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SUBJECTS AND METHODS 
 
Study design and population 
This was a perspective single-center study performed at the Pediatric Endocrinology Unit, 
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy. We 
enrolled from December 2015 to February 2017 subjects aged 6-16 years if they were 
generally healthy, obese according to the International Obesity Task Force (IOTF) criteria 
[11], and not on a weight-loss diet. Exclusion criteria were endocrine or genetic obesity, 
type 1 or type 2 diabetes, previous heart, respiratory, liver and kidney diseases, current or 
past use of hormonal or interfering therapies (lipid-lowering, hypoglycemic, or 
antihypertensive treatments). The protocol was conducted in accordance with the 
declaration of Helsinki and the Local Ethic Committee approved the study (CE 95/12). 
Informed written consent was obtained from all subjects' parents. 
 
Intervention 
Patients were evaluated at baseline (T0) and after 12 months (T12) of a behavioral 
intervention program. A trained pediatric endocrinologist and a nutritionist assessed the 
habitual diet and administered an isocaloric Mediterranen balanced diet. To evaluate food 
consumption, foods were classified according to the Italian Institute of Research on Food 
and Nutrition [12]. Food frequencies questionnaires, validated for a wide range of ages 
[13], were completed by parents. Moreover, subjects underwent a physical activity 
regimen including 45-60 minutes daily sessions of aerobic training (fast walking, running, 
ball games, or swimming). Compliance to diet and training was assessed at baseline and 
every 3 months for one year with specific questionnaires. The nutritional counselling and 
the reinforcement of healthy lifestyle habits were performed at the same time intervals.  
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Procedures 
At baseline and after the 12 months-behavioral intervention, we evaluated anthropometric 
and biochemical variables including an OGTT and we performed an echocardiographic 
and a vascular assessment (for details see chapter 2) [4]. For the purpose of this study 
and based on previous adults’ studies [14,15], compliance was defined as a negative 
change in BMI z-score ≥10% from baseline. 
 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD), absolute values or 
percentages.  Skewed variables were log transformed. The Wilcoxon signed-rank test was 
used to assess changes in the anthropometric, biochemical and cardiovascular variables.  
A two-way repeated measure ANOVA was performed to evaluate the time effect, the 
treatment effect and the interaction effects of: the negative change in BMI z-score ≥10%, 
the reduction of HOMA-IR, the number of MetS criteria according to NCEP-ATPIII 
classification [16], of SBP and of DBP on the dependent variables (cardiovascular 
parameters). Sum of squares type III was used. The following covariates were also 
subsequently introduced: sex and pubertal status. 
Statistical significance was determined at a p value of <0.05. All the statistical analyses 
were performed using R Statistical Software and SPSS for Windows version 17.0 (SPSS 
Inc., Chicago, IL, USA).   
 
RESULTS 
 
Of the 80 subjects who underwent baseline evaluation (see chapter 2), 62 accepted the 
longitudinal study while 18 refused to sign the consent for the subsequent follow-up visits 
and were excluded. During the study protocol, 4 patients were lost at follow-up and in 3 
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subjects some data (2 subjects did not perfom biochemical evaluation for the impossibility 
to find an ev access, 1 subject did not have ecochardiografic and vascular assessment)  
were not recorded and they were excluded from the final study population. Out of 55 
patient, 28 (51%) were considered compliant to behavioral program on the basis of self-
reported questionnaires and a negative change in BMI z-score ≥10% from baseline (Figure 
1). 
 
Figure 1. Study flow diagram. 
 
 
The baseline characteristics were similar in the compliant and non-compliant group and 
are shown in table 1. 
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Table 1. Baseline characteristics of 28 compliant (C) and 27 non-compliant (NC) obese subjects. 
 
 C NC P value 
Subjects 28 27  
Age (years) 11.2±2.7 11.4±2.8 ns 
Female 13 (44.8%) 13 (48.1%) ns 
Prepubertal 11 (40.7%) 9 (31.0%) ns 
Height (cm) 149.5±13.7 151.6±17.0 ns 
Height (SDS) 1.0±1.1 1.1±1.2 ns 
Weight (kg) 67.3±21.0 75.2±25.4 ns 
BMI (kg/m2) 29.3±5.2 31.8±5.7 ns 
BMI z-score 2.23±0.51 2.50±0.57 ns 
Waist (cm) 88.9±14.2 95.1±13.7 ns 
SBP (mmHg) 123.3±18.2 126.0±15.9 ns 
DBP (mmHg) 78.0±11.8 77.7±10.0 ns 
Values are number (%) or means±SD.  
Legend: BMI, body mass index; DBP, diastolic blood pressure; ns, not significant; SBP, systolic blood 
pressure; SDS, standard deviation score. 
 
Anthropometric and biochemical variables  
After the 12 months behavioral intervention, compliant subjects showed a significant 
reduction of BMI (p<0.0001), BMI z-score (p<0.0001), blood glucose at baseline (p<0.006) 
and after 120 minutes during the OGTT (p<0.007) and insulin resistance (p<0.002) and a 
significant increase of HDL-cholesterol (p<0.0001) and insulin sentivity (p<0.01). In 
contrast, non-compliant subjects had higher waist circumference (p<0.03), DBP (p<0.01) 
and a worse insulin sensitivity (p<0.01) at T12 compared to baseline (Table 2).  
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Table 2. Changes in anthropometric and biochemical variables during the 12-months behavioral 
intervention in compliant (C) and non-compliant (NC) obese children. 
 
 C NC 
N° 28 27 
 T0 T12 P value T0 T12 P value 
BMI (kg/m2) 29.3±5.2 26.1±4.0 0.0001 31.8±5.7 31.3±4.8 ns 
BMI z-score 2.20±0.51 1.60±0.64 0.0001 2.50±0.57 2.42±0.53 0.009 
Waist (cm) 88.9±14.2 86.7±11.4 ns 95.1±13.7 97.8±11.3 0.03 
SBP (mmHg) 123.3±18.2 124.5±12.3 ns 126.0±15.9 126.4±15.7 ns 
DBP (mmHg) 78.0±11.8 77.2±10.0 ns 77.7±10.0 82.8±9.0 0.01 
Glucose T0 (mg/dl) 87.7±5.7 84.3±6.5 0.006 88.5±7.9 87.6±6.6 ns 
Glucose T120 (mg/dl) 111.4±15.4 99.4±13.6 0.007 112.9±21.5 111.0±21.3 ns 
Total-c (mg/dl) 139.9±33.4 139.5±24.9 ns 145.8±25.0 146.1±24.4 ns 
HDL-c (mg/dl) 43.9±10.0 48.8±9.0 0.0001 39.9±8.6 41.7±9.9 ns 
LDL-c (mg/dl) 81.3±27.6 78.2±22.7 ns 87.0±23.9 84.0±26.4 ns 
TG (mg/dl) 69.4±32.7 61.9±27.6 ns 93.3±58.3 101.9±97.2 ns 
Uric acid (mg/dl) 5.1±1.8 5.1±1.3 ns 4.9±1.1 4.9±1.3 ns 
HOMA-IR 4.3±2.8 3.0±1.4 0.002 5.7±3.6 5.9±3.6 ns 
ISI 3.4±1.6 4.4±1.9 0.01 3.4±3.4 2.5±1.4 0.01 
QUICKI 0.32±0.03 0.33±0.02 0.02 0.31±0.03 0.30±0.02 ns 
Values are means±SD.  
Legend: BMI, body mass index; DBP, diastolic blood pressure; HOMA, homeostasis model assessment; ISI, 
Matsuda index; N°, number of subjects; ns, not significant; QUICKI, Quantitative Insulin-Sensitivity Check 
Index; SBP, systolic blood pressure; TG, triglycerides; Total-c, total cholesterol. 
 
Echocardiographic and vascular assessment  
In compliant subjects we found a significant decrease of the heart rate (p<0.01) and of 
carotid artery intima-media thickness (CIMT, p<0.01) and a significant increase of left atrial 
area (p<0.04), mitral peak early diastolic velocity (E, p<0.001), and abdominal aortic 
diameter at minimum diastolic expansion (p<0.03) at T12 compared to baseline values. 
Non-compliant patients had higher left ventricular end-diastolic diameter (LVEDD, p<0.04) 
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at T12 compared to T0. Even in this group an increase of the E (p<0.007) and a decrease 
of the CIMT (p<0.01) was shown after 12 months (Table 3). 
 
Table 3. Changes in cardiovascular variables during the 12-months behavioral intervention in compliant 
(C) and non-compliant (NC) obese children. 
  
 C NC 
N° 28 27 
 T0 T12 P value T0 T12 P value 
HR (b/min) 81.1±12.8 73.8±10.3 0.01 85.8±10.7 84.7±12.7 ns 
EF (%) 69.8±7.9 71.1±7.9 ns 70.0±9.9 69.4±6.8 ns 
FS (%) 39.7±6.3 40.5±4.6 ns 42.9±7.4 40.1±5.7 ns 
LVEDD (mm) 45.4±6.0 47.1±6.6 ns 46.1±7.7 47.0±5.1 0.04 
LVEDD z-score -0.65±0.91 -0.24±0.91 ns -1.35±1.28 -0.94±1.19 ns 
LVESD (mm) 27.5±4.8 28.0±5.1 ns 28.2±7.1 28.4±3.4 ns 
LVESD z-score -0.74±1.07 -0.52±1.13 ns -1.16±1.13 -1.03±1.24 ns 
IVSD (mm) 7.6±1.6 7.6±1.7 ns 7.7±2.0 8.2±1.9 ns 
IVSD z-score -0.28±0.94 -0.49±0.80 ns -0.09±1.05 0.30±1.06 ns 
LVPWD (mm) 7.5±1.8 7.5±1.2 ns 8.5±2.8 7.7±2.1 ns 
LVPWD z-score 0.20±0.20 0.31±1.00 ns 0.46±0.95 0.35±1.08 ns 
LAD (mm) 32.0±5.2 33.0±4.9 ns 33.7±6.1 33.4±5.4 ns 
LAD z-score 1.12±1.25 0.83±1.22 ns 1.26±1.00 1.54±0.85 ns 
Ao (mm) 24.0±3.2 25.0±3.8 ns 25.0±5.3 26.5±4.1 ns 
LA/Ao ratio 1.40±0.21 1.34±0.22 ns 1.35±0.22 1.30±0.19 ns 
LV mass (g) 113.1±47.2 123.2±40.9 ns 131.7±85.1 121.0±53.2 ns 
LV MI (g/m2) 66.8±18.3 73.9±17.8 ns 72.0±30.9 64.8±17.5 ns 
LV mass z-score -0.001±1.48 0.11±1.17 ns 0.26±1.49 -0.15±1.07 ns 
RWT 0.33±0.07 0.33±0.07 ns 0.37±0.09 0.36±0.08 ns 
LV area (cm2) 26.5±6.0 26.9±5.7 ns 26.9±7.2 26.5±5.0 ns 
LV volume (mL) 83.0±27.3 84.8±26.9 ns 86.3±36.9 83.5±23.4 ns 
LA area (cm2) 12.9±3.5 14.4±2.8 0.04 13.9±4.6 13.9±3.1 ns 
LA volume (mL) 32.5±13.9 37.2±12.5 ns 31.6±12.8 34.9±12.2 ns 
Mitral E (cm/sec) 1.02±0.20 1.12±0.18 0.001 1.04±0.24 1.21±0.59 0.007 
Mitral A (cm/sec) 0.55±0.14 0.56±0.11 ns 0.60±0.13 0.65±0.23 ns 
Mitral E/A ratio 1.91±0.43 2.02±0.44 ns 1.70±0.44 1.80±0.47 ns 
CIMT (mm) 0.62±0.17 0.52±0.09 0.01 0.61±0.11 0.55±0.05 0.01 
AoDd (mm) 10.0±1.6 10.8±1.7 0.03 10.8±2.4 11.2±1.6 ns 
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AoDs (mm) 12.5±1.9 13.1±1.5 ns 13.2±2.3 13.5±1.8 ns 
S 0.25±0.10 0.23±0.12 ns 0.24±0.15 0.21±0.11 ns 
Ep (mmHg) 201.8±128.3 249.1±161.5 ns 478.7±1140.1 253.4±149.2 ns 
Ep* 2.7±1.8 3.4±2.2 ns 6.3±15.5 3.0±1.8 ns 
BAD basal (mm) 3.40±0.74 3.49±0.54 ns 3.53±0.73 3.44±0.57 ns 
BAD after (mm) 3.48±0.68 3.38±0.88 ns 3.70±0.75 3.48±0.94 ns 
FMD (%) 3.4±14.6 0.9±10.5 ns 6.5±18.4 1.8±24.6 ns 
Values are means±SD.  
Legend: A, peak velocity of late diastolic transmitral wave; AoDd, abdominal aortic diastolic diameter; AoDs, 
abdominal aortic systolic diameter; BAD brachial artery diameter; CIMT, carotid intima-media thickness; E, 
peak velocity of early diastolic transmitral wave; EF, LV ejection fraction; Ep, pressure strain elastic modulus; 
Ep*, pressure strain normalized for diastolic blood pressure; FMD, brachial artery flow-mediated dilation; FS, 
LV fractional shortening; HR, heart rate; IVSD, interventricular septum diastolic dimension; LA, left atrium; 
LAD, LA end-systolic diameter; LV, left ventricle; LVEDD, LV end-diastolic dimension, LVESD, LV end-
systolic dimension; LVPW, LV posterior wall diastolic dimension; N°, number of subjects; ns, not significant; 
RWT, relative wall thickness; S, aortic strain. 
 
Effects of the 12-month behavioral intervention   
A two-way repeated measure ANOVA was performed to evaluate the time effect, the 
treatment effect and the interaction effects on all the cardiovascular dependent variables 
according to the negative change in BMI z-score ≥10% from baseline (Table 4). We found 
a significant effect of the interaction (time*treatment) for the mitral peak early diastolic 
velocity E (F:4.562, p<0.04) and E/A ratio (F:5.614, p<0.02), even when adjusted for sex 
and pubertal stage. We did not find any significant effect of the interaction analysing 
subjects who did and did not show a reduction of insulin resistance (HOMA-IR). Out of 55 
patients, 20 (36.4%) showed a reduction in the number of metabolic syndrome criteria 
based on NCEP-ATPIII classification. Reducing the numer of MetS criteria, LV area and 
volume decreased with a significant effect of the interaction (LV area, F:5.918, p<0.01; LV 
volume, F:3.863, p<0.05), even when adjusted for sex and pubertal stage (Figure 2). 
Furthermore, 24 (43.6%) subjects showed a decrease of the SBP and 20 (36.4%) of the 
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DBP. In both children who presented a reduction of SBP or DBP, a significant effect of the 
interaction was shown for CIMT (SBP, F:3.940, p<0.05; DBP, F:7.988, p<0.007) even 
weighted for confounding factors (Figure 3).     
 
Table 4. Cardiovascular variations obtained with multivariable analysis of repeated measure according to 
the negative change in BMI z-score ≥10% from baseline. 
 
 Time Treatment Interaction 
HR (b/min) F:6.443 
p<0.01 
F:8.459 
p<0.005 
F:2.243 
EF (%) F:0.182 F:0.112 F:0.292 
FS (%) F:0.456 F:1.952 F:1.969 
LVEDD (mm) F:5.714 
p<0.02 
F:0.026 F:0.063 
LVEDD z-score F:5.423 
p<0.02 
F:6.266 
p<0.01 
F:0.237 
LVESD (mm) F:1.482 F:0.001 F:0.167 
LVESD z-score F:1.279 F:2.931 F:0.154 
IVSD (mm) F:0.686 F:0.466 F:0.686 
IVSD z-score F:0.274 F:6.642 
p<0.01 
F:2.241 
LVPWD (mm) F:2.971 F:1.890 F:2.228 
LVPWD z-score F:1.493 F:0.295 F:2.821 
LAD (mm) F:0.824 F:0.459 F:0.285 
LAD z-score F:0.067 F:4.303 
p<0.04 
F:1.954 
Ao (mm) F:3.532 F:2.540 F:0.422 
LA/Ao ratio F:1.793 F:1.083 F:0.079 
LV mass (g) F:0.977 F:0.026 F:0.832 
LV mass index (g/m2) F:0.001 F:0.154 F:2.288 
LV mass z-score F:0.544 F:0.001 F:1.662 
RWT F:4.515 
p<0.03 
F:0.536 F:1.146 
LV area (cm2) F:0.001 F:0.001 F:0.251 
LV volume (mL) F:0.029 F:0.026 F:0.302 
LA area (cm2) F:1.296 F:0.067 F:1.856 
LA volume (mL) F:4.865 F:0.734 F:0.628 
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p<0.03 
Mitral E (cm/sec) F:9.976 
p<0.0001 
F:0.782 F:4.562 
p<0.04* 
Mitral A (cm/sec) F:1.231 F:8.224 
p<0.006 
F:0.983 
Mitral E/A ratio F:0.876 F:3.213 
 
F:5.614 
p<0.02§ 
CIMT (mm) F:8.809 
p<0.004 
F:2.608 F:1.518 
AoDd (mm) F:4.431 
p<0.04 
F:2.158 F:0.371 
AoDs (mm) F:2.248 F:1.682 F:0.176 
Aortic Strain, S F:1.587 F:0.325 F:0.017 
Ep (mmHg) F:0.642 F:1.660 F:1.437 
Ep* F:0.793 F:1.168 F:1.669 
BAD basal (mm) F:0.006 F:0.048 F:0.757 
BAD after (mm) F:1.636 F:0.734 F:0.150 
FMD (%) F:1.234 F:0.282 F:0.065 
 
A two-way repeated measure ANOVA was performed to evaluate the time effect, the treatment effect and 
the interaction effects on the dependent variables.  
After adjusting for sex and pubertal status: *p<0.05, §p<0.02. 
Legend: see Table 3 legend. 
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Figure 2.  Variations of LV area and volume in 12 months in subjects with (blu bars) or without (red bars) a 
reduction of the number of metabolic syndrome criteria according to NCEP-ATPIII classification [16].  
Data are expressed as marginal mean ± SEM. Data are significant in interaction (*p<0.01; **p<0.05). T0: 
baseline. T12: after 12 months of behavioral intervention.   
 
 
Figure 3. Variations of CIMT in 12 months in subjects with (blu bars) or without (red bars) a reduction of 
SBP (panel A) and DPB (panel B).  
Data are expressed as marginal mean ± SEM. Data are significant in interaction (*p<0.05; **p<0.007). T0: 
baseline. T12: after 12 months of behavioral intervention. 
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DISCUSSION 
 
In this study, we found an improvement of cardiovascular dysfunction in obese children 
after a 12 months intervention based on an isocaloric Mediterranean diet and aerobic 
exercise training.  
Lifestyle interventions of healthy eating, exercise, and reducing sedentary activity are the 
cornerstones therapies of obesity in childhood and adolescence. In adults, behavioral 
intervention shown a weight-loss efficacy of between 5 and 10%, often resulting in CV risk 
factors improvements [17,18]. Furthermore, pediatric lifestyle intervention trials have also 
reported improvements in body composition and metabolic parameters [19-24]. In line with 
this, we also found that children who showed a significant change in BMI z-score from 
baseline, improved glucose metabolism, HDL-cholesterol and insulin sensitivity with a 
parallel reduction of insulin resistance.  
In a previous study conducted on a population of obese children and adolescents that 
included the subjects analyzed for this perspective study, we found significant differences 
in cardiovascular structure and function compared with a group of normalweight patients 
[4]. However, cardiovascular parameters fall all in the normal ranges and highlighting the 
cardiac remodeling and the impaired vascular function in obese pediatric subjects is 
difficult with standard imaging techniques and without a control population. As the direct 
cardiovascular effects of childhood obesity are relatively mild and subtle, the effect of 
intervention programs on cardiac remodeling and cardiovascular function is difficult to 
measure. In this study, we found a significant increase of the E/A ratio (mainly related to 
the increased early diastolic velocity/E-velocities). The effect of weight loss on diastolic 
function in children has been previously reported. In a study by Ippisch et al. in morbidly 
obese adolescents aged 13-19 years, a significant reduction of BMI after 10 months from 
bariatric surgery was accompanied with a decrease of mitral A-velocities, an increase of 
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the E/A ratio and of mitral E’-velocities [25]. In addition, an exercise-training program of 8 
weeks improved diastolic function (mitral inflow A-velocities decreased, mitral Doppler 
tissue derived E’- and A’-velocities increased, and E/E’ ratio decreased) without significant 
changes of BMI in a group of obese children aged 8-14 years [26]. Ingul et al. recently 
performed a very small pilot study in 10 obese adolescents and reported that a 13-week 
aerobic interval-training program normalized systolic and diastolic cardiac function among 
obese adolescents compared with a normalweight counterparts [27]. Furthermore, Zeybek 
et al. found that a low carbohydrate diet during 6 months significantly reduced BMI and 
improved right ventricle diastolic function [28]. Taken together, these data suggest that the 
diastolic dysfunction is reversed by weight loss. Moreover, previous studies have shown 
that a reverse heart remodeling occurs after the normalization of functional changes. This 
outline the importance to continue the long-term follow-up of our patients and to improve 
strategies aimed to prevent the usually seen high drop-out rate of lifestyle intervention 
programs.  
An interesting finding of the current study is the significant effect of metabolic syndrome on 
left ventricular area and volume; in children with a reduction of the number of MetS criteria 
after the 12 months intervention, LV area and volume significantly decrease compared 
with patients with the same or a greater number of MetS criteria from the baseline. As 
previously shown, in obese children MetS was associated with greater heart dimension 
and mass with straightforward linear raises when increasing the number of matched 
criteria for MetS [4]. Subjects who met the MetS criteria, presented worst metabolic 
parameters (dyslipidemia, dysglycemia) with higher prevalence of hypertension and 
altered BMI with a significant impact on cardiac structural alterations. Reducing the 
number of MetS criteria, as reducing CV risk factors, could change heart remodeling. Our 
data confirm the influence of MetS also in the pediatric age, suggesting the usefulness of 
programs aimed at preventing or reversing MetS and the related future cardiovascular 
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dysfunction.  
In the current study, we found that in children in whom intervention reduces blood 
pressure, CIMT significantly decreased. Systemic hypertension is a common complication 
of childhood obesity. Elevated BP has been related to endothelial and smooth muscle cell 
dysfunction, arterial stiffness [29], and increased left ventricular mass [30]. Systemic 
hypertension in obese children might be due to impaired endothelial function or activation 
of the sympathetic nervous system or insulin resistance [29]. In adults, a reduction of 5 
mmHg in diastolic BP is associated with a 35% decrease of stroke [31]. Farpour-Lambert 
et al. showed, in a randomized controlled trial enrolling 44 obese prepubertal children that 
a 3 months exercise training programme significantly reduced systolic and diastolic BP 
and improved arterial stiffness and CIMT [32]. Other pediatric studies have demonstrated 
improvements in flow-mediated dilatation and intima-media thickness with diet alone, 
exercise alone or diet and exercise [14,33,34]. Furthermore, in adults, 1 SD increase in 
CIMT has been associated with a 2-fold raised risk of ischemic stroke or myocardial 
infarction [35]; thus changes of CIMT could determine important health gains at a 
population level.  
Our study has several potential limitations. The major limit is the relatively small size of the 
population. Moreover, our study was not a randomized controlled trial. We perform a 
prospective data collection, which is certainly susceptible to selection bias. Finally a more 
extensive use of vascular imaging modalities including speckle tracking echocardiography 
and cardiac MRI would have certainly improved the results of the current study.  
In conclusion, this study shows that a healthy-lifestyle intervention could reverse 
cardiovascular dysfunction in obese children. This effect is probably mediated by several 
mechanisms as the reduction of body weight, the improvement of metabolic status and the 
reduction of systemic blood pressure.  
Further larger studies and randomized trials are warranted to confirm our findings and 
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future research should investigate the molecular basis of these changes.  
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Chapter 5 
Conclusions and  
future perspectives 
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The childhood obesity epidemic is one of the most alarming public health issues 
worldwide. Pediatric obesity is associated with a wide range of severe complications, 
exponentially increasing the risk of premature morbidity and mortality and negatively 
impacting the prevalence and the age of cardiovascular events and death [1,2]. This thesis 
demonstrates that, beyond traditional cardiovascular risk factors, pediatric obesity is 
currently associated with cardiovascular impairement. This data requires immediate 
attention in order to precociously identify children at greater risk of cardiovascular 
dysfunction. With this purpose, the finding of clinical markers, like serum uric acid, insulin 
resitance and estimated glomerular filtration rate, helpful to recognize an “unhealthy” 
metabolic profile and to stratify risk among pediatric population is crucial. Furtermore, it is 
well known that childhood obesity is highly predictive of adult obesity [3] while recent 
evidences show that some serious complications and adverse events could be prevented 
by reversing this trend and gaining a normal weight before puberty [4]. In this thesis, we 
show that cardiovascular damage could be revesed by a healthy-lifestyle program, the 
cornestone of obesity treatment during pediatric age and this highlight the importance to 
establish large behavioral programs with trained personnel, in qualify units, and with a 
close follow-up to prevent drop-outs and to obtain long-term results. In this perspective, 
the role of the pediatric community to prevent obesity and its complications, to precocously 
identify children at higher risk and to promptly establish therapeutic measures is crucial for 
the whole community and the pediatric age represents a window of opportunities for the 
future public health.    
 
Future perspectives 
The cumulative burden of “traditional” cardiovascular risk factors related to obesity has 
been related to cardiovascular impairment and atherosclerosis. However, recent studies 
have focused on novel mediators of cardiovascular dysfunction. It is well known that 
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obesity is characterized by insulin resistance and a low-grade inflammation. Particularly, 
dysfunctional visceral adipose tissue could be implicated in inflammation, oxidative stress, 
and angiogenesis (Figure 1) [5]. Furthermore, it has been established that free fatty acids 
(FFA) represent an important link between obesity, insulin resistance, and inflammation 
[6].  
 
Figure 1. Pathophysiology of cardiovascular dysfunction in “adiposopathy” of obesity [5].  
 
 
However, seen that not all insulin resistant subjects have elevated plasma FFA levels 
other mechanisms should be involved. One of these appears to be endoplasmic reticulum 
(ER) stress [7]. The ER is a main site for protein and for lipid and sterol synthesis. 
Ribosomes attached to the ER membranes release newly synthesized peptides into the 
ER lumen, where protein chaperones and foldases assist in the proper posttranslational 
modification and folding of these peptides. The folded proteins are then released to the 
Golgi complex for final modification. If the influx of misfolded or unfolded peptides exceeds 
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the ER folding capacity, ER stress ensues. Three proximal ER stress sensors have been 
identified. They are inositol-requiring enzyme (IRE)-1, PKR-like ER protein kinase (PERK), 
and activating transcription factor-6. These sensors trigger activation of pathways, termed 
the unfolded protein response (UPR), which act to reduce the ER stress. 
In vitro and animal models suggest that ER stress could represent a response to an 
excessive macronutrient intake and that ER stress can lead to the development of insulin 
resistance and inflammation via the phosphorylation and activation of C-jun N- terminal 
kinase (JNK), the activation and nuclear translocation of nuclear factor κB (NFκB), and the 
production of reactive oxygen species (ROS) [8,9]. So far, however, ER stress has only 
been reported in some rodent models of obesity and few studies exist only in adult obese 
human subjects [10].  
Our preliminary data show that calreticulin (CRT) and ERp57, ER stress-responsive 
proteins, have higher concentrations in plasmatic samples of 14 obese children compared 
to a group of normalweight age- sex- and pubertal status matched controls (Figure 2) 
suggesting activation of UPR and therefore the presence of ER stress. 
 
Figure 2. Preliminary data: calreticulin (CRT) (panel A) and ERp57 (panel B) plasmatic levels (ng/mL) in 
14 obese children and lean controls. 
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The chaperone CRT facilitates protein folding by shielding unfolded protein regions from 
surrounding proteins, thus preventing aggregation. In addition, CRT and calnexin (CLNX) 
act in the quality-control machinery of the ER that monitors the glycosylation status of 
proteins and determines whether a molecule is exported to the Golgi complex or targeted 
for ER-associated degradation [8]. ERp57 participates in protein folding in association with 
CRT and CLNX (Figure 3) [11]. 
Figure 3. Multiple binding partners and functions of ERp57. ERp57 can be localized to the ER, nucleus, 
cytoplasm, mitochondria and plasma membrane. In the ER, ERp57's b-b′ domains associate with the P-
domain of CRT/CLNX and ERp57 a and a′ active domains mediate the catalysis of CRT/CLNX bound 
substrates [11].  
 
The finding of the presence of ER stress from pediatric age could lead novel insights to the 
complex mechanisms involved in obesity-related insulin resistance and inflammation and 
therefore atherosclerosis and cardiovascular damage. Furthermore, we will investigate if a 
healthy-lifestyle intervention and the reduction of nutrients intake could attenuate the ER 
stress, improving insulin resistance and inflammation and finally leading to a better 
metabolic profile.  
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